Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
transactivates	O
latent	B-protein
membrane	I-protein
protein	I-protein
LMP1	B-protein
.	O

Several	O
lines	O
of	O
evidence	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	O
EBNA-2	B-protein
)	O
or	O
leader	B-protein
protein	I-protein
(	O
EBNA-LP	B-protein
)	O
affects	O
expression	O
of	O
the	O
EBV	B-protein
latent	I-protein
infection	I-protein
membrane	I-protein
protein	I-protein
LMP1	B-protein
.	O

We	O
now	O
demonstrate	O
the	O
following	O
.	O

(	O
i	O
)	O
Acute	O
transfection	O
and	O
expression	O
of	O
EBNA-2	B-protein
under	O
control	O
of	O
simian	B-DNA
virus	I-DNA
40	I-DNA
or	I-DNA
Moloney	I-DNA
murine	I-DNA
leukemia	I-DNA
virus	I-DNA
promoters	I-DNA
resulted	O
in	O
increased	O
LMP1	B-protein
expression	O
in	O
P3HR-1-infected	B-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
and	O
the	O
P3HR-1	B-cell_line
or	O
Daudi	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

(	O
ii	O
)	O
Transfection	O
and	O
expression	O
of	O
EBNA-LP	B-protein
alone	O
had	O
no	O
effect	O
on	O
LMP1	B-protein
expression	O
and	O
did	O
not	O
act	O
synergistically	O
with	O
EBNA-2	B-protein
to	O
affect	O
LMP1	B-protein
expression	O
.	O

(	O
iii	O
)	O
LMP1	B-protein
expression	O
in	O
Daudi	B-cell_line
and	O
P3HR-1-infected	B-cell_line
cells	I-cell_line
was	O
controlled	O
at	O
the	O
mRNA	B-RNA
level	O
,	O
and	O
EBNA-2	B-protein
expression	O
in	O
Daudi	B-cell_line
cells	I-cell_line
increased	O
LMP1	B-RNA
mRNA	I-RNA
.	O

(	O
iv	O
)	O
No	O
other	O
EBV	B-DNA
genes	I-DNA
were	O
required	O
for	O
EBNA-2	B-protein
transactivation	O
of	O
LMP1	B-protein
since	O
cotransfection	O
of	O
recombinant	B-DNA
EBNA-2	I-DNA
expression	I-DNA
vectors	I-DNA
and	O
genomic	O
LMP1	B-DNA
DNA	I-DNA
fragments	I-DNA
enhanced	O
LMP1	B-protein
expression	O
in	O
the	O
EBV-negative	B-cell_line
B-lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
BJAB	B-cell_line
,	O
Louckes	B-cell_line
,	O
and	O
BL30	B-cell_line
.	O

(	O
v	O
)	O
An	O
EBNA-2-responsive	B-DNA
element	I-DNA
was	O
found	O
within	O
the	O
-512	B-DNA
to	I-DNA
+40	I-DNA
LMP1	I-DNA
DNA	I-DNA
since	O
this	O
DNA	O
linked	O
to	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	I-DNA
was	O
transactivated	O
by	O
cotransfection	O
with	O
an	O
EBNA-2	B-DNA
expression	I-DNA
vector	I-DNA
.	O

(	O
vi	O
)	O
The	O
EBV	O
type	O
2	O
EBNA-2	B-protein
transactivated	O
LMP1	B-protein
as	O
well	O
as	O
the	O
EBV	B-protein
type	I-protein
1	I-protein
EBNA-2	I-protein
.	O

(	O
vii	O
)	O
Two	O
deletions	O
within	O
the	O
EBNA-2	B-protein
gene	O
which	O
rendered	O
EBV	O
transformation	O
incompetent	O
did	O
not	O
transactivate	O
LMP1	B-protein
,	O
whereas	O
a	O
transformation-competent	B-DNA
EBNA-2	I-DNA
deletion	I-DNA
mutant	I-DNA
did	O
transactivate	O
LMP1	B-protein
.	O

LMP1	B-protein
is	O
a	O
potent	O
effector	O
of	O
B-lymphocyte	O
activation	O
and	O
can	O
act	O
synergistically	O
with	O
EBNA-2	B-protein
to	O
induce	O
cellular	O
CD23	O
gene	O
expression	O
.	O

Thus	O
,	O
EBNA-2	B-protein
transactivation	O
of	O
LMP1	B-protein
amplifies	O
the	O
biological	O
impact	O
of	O
EBNA-2	B-protein
and	O
underscores	O
its	O
central	O
role	O
in	O
EBV-induced	O
growth	O
transformation	O
.	O

JoURNAL	NULL
OF	NULL
ViroLOGY	NULL
,	NULL
July	NULL
1990	NULL
,	NULL
p.	NULL
3407-3416	NULL
0022-538	NULL
X/90/073407-10	NULL
$	NULL
02.00/0	NULL
Copyright	NULL
Â©	NULL
1990	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

64	NULL
,	NULL
No	NULL
.	NULL

7	NULL
Epstein-Barr	NULL
Virus	NULL
Nuclear	NULL
Antigen	NULL
2	NULL
Transactivates	NULL
Latent	NULL
Membrane	NULL
Protein	NULL
FRED	NULL
WANG	NULL
,	NULL
*	NULL
SO-FAI	NULL
TSANG	NULL
,	NULL
MICHAEL	NULL
G.	NULL
KURILLA	NULL
,	NULL
JEFFREY	NULL
I.	NULL
COHEN	NULL
,	NULL
anp	NULL
ELLIOTT	NULL
KIEFF	NULL
Departments	NULL
of	NULL
Medicine	NULL
and	NULL
Microbiology	NULL
and	NULL
Molecular	NULL
Genetics	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
75	NULL
Francis	NULL
Street	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02115	NULL
Received	NULL
17	NULL
January	NULL
1990/Accepted	NULL
2	NULL
April	NULL
1990	NULL
Several	NULL
lines	NULL
of	NULL
evidence	NULL
are	NULL
compatible	NULL
with	NULL
the	NULL
hypothesis	NULL
that	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
nuclear	NULL
antigen	NULL
2	NULL
(	NULL
EBNA-2	NULL
)	NULL
or	NULL
leader	NULL
protein	NULL
(	NULL
EBNA-LP	NULL
)	NULL
affects	NULL
expression	NULL
of	NULL
the	NULL
EBV	NULL
latent	NULL
infection	NULL
membrane	NULL
protein	NULL
LMP1	NULL
.	NULL

We	NULL
now	NULL
demonstrate	NULL
the	NULL
following	NULL
.	NULL

(	NULL
i	NULL
)	NULL
Acute	NULL
transfection	NULL
and	NULL
expression	NULL
of	NULL
EBNA-2	NULL
under	NULL
control	NULL
of	NULL
simian	NULL
virus	NULL
40	NULL
or	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
promoters	NULL
resulted	NULL
in	NULL
increased	NULL
LMP1	NULL
expression	NULL
in	NULL
P3HR-1-infected	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cells	NULL
and	NULL
the	NULL
P3HR-1	NULL
or	NULL
Daudi	NULL
cell	NULL
line	NULL
.	NULL

(	NULL
ii	NULL
)	NULL
Transfection	NULL
and	NULL
expression	NULL
of	NULL
EBNA-LP	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
LMP1	NULL
expression	NULL
and	NULL
did	NULL
not	NULL
act	NULL
synergistically	NULL
with	NULL
EBNA-2	NULL
to	NULL
affect	NULL
LMP1	NULL
expression	NULL
.	NULL

(	NULL
iii	NULL
)	NULL
LMP1	NULL
expression	NULL
in	NULL
Daudi	NULL
and	NULL
P3HR-1-infected	NULL
cells	NULL
was	NULL
controlled	NULL
at	NULL
the	NULL
mRNA	NULL
level	NULL
,	NULL
and	NULL
EBNA-2	NULL
expression	NULL
in	NULL
Daudi	NULL
cells	NULL
increased	NULL
LMP1	NULL
mRNA	NULL
.	NULL

(	NULL
iv	NULL
)	NULL
No	NULL
other	NULL
EBV	NULL
genes	NULL
were	NULL
required	NULL
for	NULL
EBNA-2	NULL
transactivation	NULL
of	NULL
LMP1	NULL
since	NULL
cotransfection	NULL
of	NULL
recombinant	NULL
EBNA-2	NULL
expression	NULL
vectors	NULL
and	NULL
genomic	NULL
LMP1	NULL
DNA	NULL
fragments	NULL
enhanced	NULL
LMP1	NULL
expression	NULL
in	NULL
the	NULL
EBV-negative	NULL
B-lymphoma	NULL
cell	NULL
lines	NULL
BJAB	NULL
,	NULL
Louckes	NULL
,	NULL
and	NULL
BL30	NULL
.	NULL

(	NULL
v	NULL
)	NULL
An	NULL
EBNA-2-responsive	NULL
element	NULL
was	NULL
found	NULL
within	NULL
the	NULL
-512	NULL
to	NULL
+40	NULL
LMP1	NULL
DNA	NULL
since	NULL
this	NULL
DNA	NULL
linked	NULL
to	NULL
a	NULL
chloramphenicol	NULL
acetyltransferase	NULL
reporter	NULL
gene	NULL
was	NULL
transactivated	NULL
by	NULL
cotransfection	NULL
with	NULL
an	NULL
EBNA-2	NULL
expression	NULL
vector	NULL
.	NULL

(	NULL
vi	NULL
)	NULL
The	NULL
EBV	NULL
type	NULL
2	NULL
EBNA-2	NULL
transactivated	NULL
LMPI1	NULL
as	NULL
well	NULL
as	NULL
the	NULL
EBV	NULL
type	NULL
1	NULL
EBNA-2	NULL
.	NULL

(	NULL
vii	NULL
)	NULL
Two	NULL
deletions	NULL
within	NULL
the	NULL
EBNA-2	NULL
gene	NULL
which	NULL
rendered	NULL
EBV	NULL
transformation	NULL
incompetent	NULL
did	NULL
not	NULL
transactivate	NULL
LMP1	NULL
,	NULL
whereas	NULL
a	NULL
transformation-competent	NULL
EBNA-2	NULL
deletion	NULL
mutant	NULL
did	NULL
transactivate	NULL
LMP1	NULL
.	NULL

LMP1	NULL
is	NULL
a	NULL
potent	NULL
effector	NULL
of	NULL
B-lymphocyte	NULL
activation	NULL
and	NULL
can	NULL
act	NULL
synergistically	NULL
with	NULL
EBNA-2	NULL
to	NULL
induce	NULL
cellular	NULL
CD23	NULL
gene	NULL
expression	NULL
.	NULL

Thus	NULL
,	NULL
EBNA-2	NULL
transactivation	NULL
of	NULL
LMP1	NULL
amplifies	NULL
the	NULL
biological	NULL
impact	NULL
of	NULL
EBNA-2	NULL
and	NULL
underscores	NULL
its	NULL
central	NULL
role	NULL
in	NULL
EBV-induced	NULL
growth	NULL
transformation	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
can	NULL
cause	NULL
B-lymphoprolifera-tive	NULL
disorders	NULL
in	NULL
immunocompromised	NULL
or	NULL
genetically	NULL
susceptible	NULL
humans	NULL
(	NULL
6	NULL
,	NULL
33	NULL
)	NULL
and	NULL
in	NULL
marmosets	NULL
(	NULL
42	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
,	NULL
EBV	NULL
infection	NULL
efficiently	NULL
induces	NULL
immunoglobulin	NULL
secretion	NULL
and	NULL
perpetual	NULL
B-lymphocyte	NULL
proliferation	NULL
(	NULL
17	NULL
,	NULL
32	NULL
)	NULL
.	NULL

The	NULL
functions	NULL
of	NULL
the	NULL
six	NULL
nuclear	NULL
proteins	NULL
(	NULL
EBV	NULL
nuclear	NULL
antigen	NULL
[	NULL
EBNA	NULL
]	NULL
-1	NULL
,	NULL
-2	NULL
,	NULL
-3A	NULL
,	NULL
-3B	NULL
,	NULL
-3C	NULL
,	NULL
and	NULL
leader	NULL
protein	NULL
[	NULL
EBNA-LP	NULL
]	NULL
)	NULL
and	NULL
three	NULL
latent	NULL
membrane	NULL
proteins	NULL
(	NULL
LMP1	NULL
,	NULL
LMP2A	NULL
,	NULL
and	NULL
LMP2B	NULL
)	NULL
expressed	NULL
from	NULL
the	NULL
viral	NULL
genome	NULL
during	NULL
latent	NULL
,	NULL
growth-transforming	NULL
infection	NULL
are	NULL
being	NULL
actively	NULL
investigated	NULL
(	NULL
see	NULL
reference	NULL
20	NULL
for	NULL
a	NULL
review	NULL
)	NULL
.	NULL

LMPI	NULL
appears	NULL
to	NULL
be	NULL
important	NULL
for	NULL
growth	NULL
transformation	NULL
since	NULL
transfection	NULL
and	NULL
expression	NULL
in	NULL
rodent	NULL
fibroblasts	NULL
results	NULL
in	NULL
reduced	NULL
serum	NULL
dependence	NULL
,	NULL
anchorage	NULL
independence	NULL
,	NULL
and	NULL
tumorigenicity	NULL
in	NULL
nude	NULL
mice	NULL
(	NULL
2	NULL
,	NULL
44	NULL
,	NULL
45	NULL
)	NULL
.	NULL

In	NULL
various	NULL
EBV-negative	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cells	NULL
,	NULL
LMPI	NULL
induces	NULL
phenotypic	NULL
changes	NULL
characteristic	NULL
of	NULL
B-cell	NULL
activation	NULL
including	NULL
induction	NULL
of	NULL
cellular	NULL
adhesion	NULL
molecules	NULL
,	NULL
transferrin	NULL
recep-tor	NULL
,	NULL
CD21	NULL
,	NULL
CD23	NULL
,	NULL
CD39	NULL
,	NULL
CD44	NULL
,	NULL
and	NULL
vimentin	NULL
(	NULL
3	NULL
,	NULL
46	NULL
,	NULL
49	NULL
)	NULL
.	NULL

EBNA-2	NULL
or	NULL
EBNA-LP	NULL
is	NULL
necessary	NULL
for	NULL
B-lymphocyte	NULL
growth	NULL
transformation	NULL
.	NULL

The	NULL
Daudi	NULL
and	NULL
P3HR-1	NULL
EBV	NULL
strains	NULL
are	NULL
deleted	NULL
for	NULL
EBNA-2	NULL
and	NULL
part	NULL
of	NULL
the	NULL
EBNA-LP	NULL
genes	NULL
(	NULL
4	NULL
,	NULL
15	NULL
,	NULL
16	NULL
,	NULL
19	NULL
,	NULL
22	NULL
,	NULL
34	NULL
)	NULL
and	NULL
are	NULL
unable	NULL
to	NULL
immortalize	NULL
B	NULL
lymphocytes	NULL
(	NULL
19	NULL
,	NULL
28	NULL
)	NULL
.	NULL

P3HR-1	NULL
recombination	NULL
with	NULL
other	NULL
EBV	NULL
strains	NULL
or	NULL
cloned	NULL
EBV	NULL
DNA	NULL
fragments	NULL
which	NULL
results	NULL
in	NULL
reconstitution	NULL
of	NULL
the	NULL
P3HR-1	NULL
deletion	NULL
restores	NULL
the	NULL
transforming	NULL
phenotype	NULL
(	NULL
7	NULL
,	NULL
13	NULL
,	NULL
43	NULL
)	NULL
.	NULL

EBNA-2	NULL
is	NULL
essential	NULL
for	NULL
growth	NULL
transformation	NULL
since	NULL
truncation	NULL
(	NULL
13	NULL
)	NULL
or	NULL
deletions	NULL
within	NULL
the	NULL
EBNA-2	NULL
open	NULL
reading	NULL
frame	NULL
(	NULL
7	NULL
)	NULL
result	NULL
in	NULL
transformation-incompetent	NULL
EBV	NULL
.	NULL

In	NULL
rat-l	NULL
rodent	NULL
fibroblasts	NULL
,	NULL
EBNA-2	NULL
reduces	NULL
serum	NULL
dependency	NULL
but	NULL
does	NULL
not	NULL
affect	NULL
contact	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

3407	NULL
inhibition	NULL
,	NULL
anchorage	NULL
independence	NULL
,	NULL
or	NULL
tumorigenicity	NULL
(	NULL
9	NULL
)	NULL
.	NULL

In	NULL
the	NULL
EBV-negative	NULL
B-lymphoma	NULL
cell	NULL
lines	NULL
Louckes	NULL
and	NULL
BJAB	NULL
,	NULL
EBNA-2	NULL
alone	NULL
induces	NULL
CD21	NULL
and	NULL
CD23	NULL
expression	NULL
without	NULL
concomitantly	NULL
inducing	NULL
other	NULL
activation	NULL
antigens	NULL
or	NULL
cellular	NULL
adhesion	NULL
molecules	NULL
(	NULL
47	NULL
,	NULL
48	NULL
)	NULL
.	NULL

Several	NULL
experiments	NULL
suggest	NULL
that	NULL
EBNA-2	NULL
or	NULL
EBNA-LP	NULL
also	NULL
affects	NULL
LMP1	NULL
expression	NULL
.	NULL

First	NULL
,	NULL
EBNA-2	NULL
and	NULL
LMP1	NULL
are	NULL
often	NULL
difficult	NULL
to	NULL
detect	NULL
in	NULL
early	NULL
passage	NULL
Burkitt	NULL
's	NULL
tumor	NULL
cell	NULL
lines	NULL
and	NULL
coordinately	NULL
increase	NULL
in	NULL
abundance	NULL
with	NULL
cell	NULL
passage	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
EBV-negative	NULL
Burkitt	NULL
's	NULL
tumor	NULL
cells	NULL
stably	NULL
infected	NULL
with	NULL
the	NULL
P3HR-1	NULL
EBV	NULL
strain	NULL
do	NULL
not	NULL
express	NULL
EBNA-2	NULL
,	NULL
a	NULL
normal	NULL
EBNA-LP	NULL
,	NULL
or	NULL
LMP1	NULL
,	NULL
while	NULL
cells	NULL
stably	NULL
infected	NULL
with	NULL
EBV	NULL
strain	NULL
B95-8	NULL
express	NULL
EBNA-2	NULL
,	NULL
a	NULL
complete	NULL
EBNA-LP	NULL
,	NULL
and	NULL
LMPI1	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Third	NULL
,	NULL
B	NULL
cells	NULL
immortalized	NULL
by	NULL
recombinant	NULL
P3HR-1	NULL
with	NULL
a	NULL
restored	NULL
EBNA-2	NULL
and	NULL
EBNA-LP	NULL
express	NULL
normal	NULL
LMP1	NULL
levels	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Fourth	NULL
,	NULL
cat	NULL
reporter	NULL
gene	NULL
expression	NULL
under	NULL
control	NULL
of	NULL
the	NULL
LMP1	NULL
promoter	NULL
(	NULL
-512	NULL
to	NULL
+40	NULL
)	NULL
was	NULL
higher	NULL
in	NULL
cells	NULL
stably	NULL
infected	NULL
with	NULL
B95-8	NULL
EBV	NULL
,	NULL
which	NULL
expressed	NULL
EBNA-2	NULL
and	NULL
EBNA-LP	NULL
,	NULL
compared	NULL
with	NULL
cells	NULL
stably	NULL
infected	NULL
with	NULL
P3HR-1	NULL
EBV	NULL
,	NULL
which	NULL
lacks	NULL
EBNA-2	NULL
and	NULL
a	NULL
complete	NULL
EBNA-LP	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
objective	NULL
of	NULL
the	NULL
experiments	NULL
reported	NULL
here	NULL
is	NULL
to	NULL
investigate	NULL
directly	NULL
whether	NULL
EBNA-2	NULL
and	NULL
EBNA-LP	NULL
,	NULL
either	NULL
individually	NULL
or	NULL
together	NULL
,	NULL
transactivate	NULL
LMP1	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
lines	NULL
.	NULL

1B4	NULL
is	NULL
a	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
latently	NULL
infected	NULL
with	NULL
EBV	NULL
.	NULL

BJAB	NULL
is	NULL
an	NULL
EBV-negative	NULL
B-lymphoma	NULL
cell	NULL
line	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Louckes	NULL
,	NULL
BL30	NULL
,	NULL
and	NULL
BL41	NULL
are	NULL
EBV-negative	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
lines	NULL
.	NULL

Daudi	NULL
(	NULL
19	NULL
)	NULL
and	NULL
P3HR-1	NULL
(	NULL
HHS14-16	NULL
kindly	NULL
provided	NULL
by	NULL
G.	NULL
Miller	NULL
[	NULL
35	NULL
]	NULL
)	NULL
are	NULL
EBV-infected	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
lines	NULL
.	NULL

BL3O/P3HR-1	NULL
,	NULL
BL30/B95-8	NULL
,	NULL
BL41/P3HR-1	NULL
,	NULL
and	NULL
BL41/B95-8	NULL
are	NULL
EBV-neg-	NULL
3408	NULL
WANG	NULL
ET	NULL
AL	NULL
.	NULL

ative	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
lines	NULL
which	NULL
have	NULL
been	NULL
stably	NULL
infected	NULL
in	NULL
vitro	NULL
with	NULL
the	NULL
respective	NULL
EBV	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
G.	NULL
Lenoir	NULL
[	NULL
5	NULL
]	NULL
)	NULL
.	NULL

M12	NULL
and	NULL
A20	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
A.	NULL
Abbas	NULL
)	NULL
are	NULL
spontaneous	NULL
mouse	NULL
B-lymphoma	NULL
cell	NULL
lines	NULL
(	NULL
21	NULL
)	NULL
.	NULL

MT-2	NULL
is	NULL
a	NULL
human	NULL
T-cell-lymphotropic	NULL
virus	NULL
type	NULL
I-transformed	NULL
human	NULL
T-cell	NULL
line	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
G.	NULL
Tosato	NULL
and	NULL
R.	NULL
Yarchoan	NULL
[	NULL
29	NULL
]	NULL
)	NULL
.	NULL

The	NULL
human	NULL
cervical	NULL
carcinoma	NULL
cell	NULL
line	NULL
HeLa	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Rockville	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

.	NULL

Plasmids	NULL
.	NULL

The	NULL
pSGS	NULL
expression	NULL
vector	NULL
(	NULL
Stratagene	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
Calif.	NULL
)	NULL
contains	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
(	NULL
SV40	NULL
)	NULL
early	NULL
promoter	NULL
,	NULL
a	NULL
beta-globin	NULL
intron	NULL
,	NULL
and	NULL
an	NULL
SV40	NULL
polyadenylation	NULL
signal	NULL
.	NULL

EBV	NULL
DNA	NULL
fragments	NULL
encoding	NULL
the	NULL
EBV	NULL
type	NULL
1	NULL
EBNA-2	NULL
(	NULL
nucleotides	NULL
48475	NULL
to	NULL
50306	NULL
of	NULL
B95-8	NULL
EBV	NULL
)	NULL
or	NULL
EBV	NULL
type	NULL
2	NULL
EBNA-2	NULL
(	NULL
an	NULL
Rsal	NULL
partial	NULL
digest	NULL
of	NULL
the	NULL
Ag876	NULL
EBV	NULL
BamHI	NULL
D1	NULL
fragment	NULL
)	NULL
were	NULL
cloned	NULL
into	NULL
the	NULL
pSGS	NULL
vector	NULL
and	NULL
are	NULL
referred	NULL
to	NULL
as	NULL
SV-EBINA2	NULL
and	NULL
SV-EB2NA2	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
pZipNeoSV	NULL
(	NULL
X	NULL
)	NULL
-1	NULL
expression	NULL
vectors	NULL
containing	NULL
the	NULL
EBV	NULL
type	NULL
1	NULL
and	NULL
type	NULL
2	NULL
EBNA-2	NULL
open	NULL
reading	NULL
frames	NULL
only	NULL
have	NULL
been	NULL
previously	NULL
described	NULL
(	NULL
9	NULL
,	NULL
48	NULL
)	NULL
and	NULL
are	NULL
referred	NULL
to	NULL
here	NULL
as	NULL
pZip-EBINA2	NULL
and	NULL
pZip-EB2NA2	NULL
.	NULL

The	NULL
HindIII	NULL
fragments	NULL
of	NULL
each	NULL
vector	NULL
were	NULL
also	NULL
cloned	NULL
into	NULL
pUCI18	NULL
to	NULL
generate	NULL
a	NULL
smaller	NULL
plasmid	NULL
containing	NULL
the	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
(	NULL
MuLV	NULL
)	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
and	NULL
EBNA-2	NULL
gene	NULL
(	NULL
LTR-EBINA2	NULL
and	NULL
LTR-EB2NA2	NULL
)	NULL
.	NULL

The	NULL
pZip-ELP	NULL
expression	NULL
vector	NULL
contains	NULL
the	NULL
EBNA-LP	NULL
open	NULL
reading	NULL
frame	NULL
derived	NULL
from	NULL
an	NULL
EcoRI-to-FnudlI	NULL
fragment	NULL
of	NULL
the	NULL
T65	NULL
cDNA	NULL
(	NULL
39	NULL
)	NULL
.	NULL

These	NULL
vectors	NULL
express	NULL
the	NULL
appropriate	NULL
EBV	NULL
protein	NULL
after	NULL
stable	NULL
transfection	NULL
into	NULL
human	NULL
EBV-negative	NULL
B-lymphoma	NULL
cells	NULL
(	NULL
47	NULL
,	NULL
48	NULL
)	NULL
.	NULL

The	NULL
LTR-ELP	NULL
vector	NULL
is	NULL
the	NULL
HindIII	NULL
fragment	NULL
of	NULL
pZip-T65	NULL
and	NULL
contains	NULL
the	NULL
MuLV	NULL
LTR	NULL
and	NULL
the	NULL
bicistronic	NULL
T6S	NULL
cDNA	NULL
.	NULL

LTR-ELP	NULL
expresses	NULL
only	NULL
EBNA-LP	NULL
after	NULL
transfection	NULL
into	NULL
EBV-negative	NULL
B-lymphoma	NULL
cells	NULL
(	NULL
47	NULL
,	NULL
48	NULL
)	NULL
.	NULL

EBNA-2	NULL
mutations	NULL
were	NULL
all	NULL
derived	NULL
from	NULL
the	NULL
B95-8	NULL
EBV	NULL
EBNA-2	NULL
(	NULL
nucleotides	NULL
48475	NULL
to	NULL
50306	NULL
)	NULL
and	NULL
cloned	NULL
into	NULL
the	NULL
pZipNeoSV	NULL
(	NULL
X	NULL
)	NULL
-1	NULL
expression	NULL
vector	NULL
.	NULL

Deletions	NULL
were	NULL
constructed	NULL
by	NULL
restriction	NULL
enzyme	NULL
digestion	NULL
and	NULL
are	NULL
named	NULL
according	NULL
to	NULL
the	NULL
deleted	NULL
EBNA-2	NULL
amino	NULL
acids	NULL
(	NULL
pZip-E2d19-115	NULL
,	NULL
HinclI	NULL
to	NULL
BamHI	NULL
;	NULL
pZip-E2d148-324	NULL
,	NULL
BsfEIll	NULL
to	NULL
Ball	NULL
;	NULL
pZip-E2d200-234	NULL
,	NULL
StuI	NULL
to	NULL
Stul	NULL
)	NULL
.	NULL

The	NULL
Ny	NULL
,	NULL
,	NULL
plasmid	NULL
contains	NULL
the	NULL
BamHI	NULL
Ny	NULL
,	NULL
,	NULL
fragment	NULL
of	NULL
B95-8	NULL
EBV	NULL
DNA	NULL
from	NULL
nucleotide	NULL
166,614	NULL
across	NULL
the	NULL
terminal	NULL
repeats	NULL
to	NULL
nucleotide	NULL
3,955	NULL
in	NULL
pUC18	NULL
.	NULL

The	NULL
NdEco	NULL
plasmid	NULL
(	NULL
nucleotides	NULL
166,614	NULL
to	NULL
1	NULL
)	NULL
was	NULL
derived	NULL
by	NULL
digestion	NULL
of	NULL
Ny	NULL
,	NULL
,	NULL
.	NULL

,	NULL
with	NULL
EcoRI	NULL
and	NULL
cloning	NULL
into	NULL
pUC18	NULL
.	NULL

Both	NULL
constructs	NULL
appear	NULL
to	NULL
have	NULL
only	NULL
one	NULL
copy	NULL
of	NULL
the	NULL
terminal	NULL
repeat	NULL
by	NULL
restriction	NULL
enzyme	NULL
digests	NULL
.	NULL

The	NULL
-512/+40	NULL
LMPCAT	NULL
construct	NULL
was	NULL
derived	NULL
by	NULL
cloning	NULL
the	NULL
-512	NULL
to	NULL
+40	NULL
latent	NULL
membrane	NULL
protein	NULL
(	NULL
LMP1	NULL
)	NULL
upstream	NULL
sequences	NULL
relative	NULL
to	NULL
the	NULL
BNLFI	NULL
start	NULL
site	NULL
into	NULL
the	NULL
Bglll	NULL
site	NULL
of	NULL
pCAT	NULL
(	NULL
11	NULL
)	NULL
.	NULL

pCAT	NULL
and	NULL
pSV2CAT	NULL
contain	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
(	NULL
cat	NULL
)	NULL
without	NULL
and	NULL
with	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
,	NULL
respectively	NULL
.	NULL

Transfections	NULL
.	NULL

A	NULL
total	NULL
of	NULL
5	NULL
x	NULL
10Â°	NULL
cells	NULL
in	NULL
log-phase	NULL
growth	NULL
were	NULL
suspended	NULL
in	NULL
0.3	NULL
ml	NULL
of	NULL
RPMI	NULL
1640	NULL
medium	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
at	NULL
room	NULL
temperature	NULL
and	NULL
placed	NULL
in	NULL
a	NULL
Gene	NULL
Pulser	NULL
cuvette	NULL
(	NULL
Bio-Rad	NULL
Laboratories	NULL
,	NULL
Richmond	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

A	NULL
15-ug	NULL
sample	NULL
of	NULL
each	NULL
uncut	NULL
plasmid	NULL
DNA	NULL
which	NULL
had	NULL
been	NULL
purified	NULL
twice	NULL
on	NULL
cesium	NULL
chloride	NULL
gradients	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cuvette	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
total	NULL
DNA	NULL
were	NULL
added	NULL
to	NULL
each	NULL
sample	NULL
within	NULL
any	NULL
single	NULL
experiment	NULL
.	NULL

Cells	NULL
were	NULL
electropo-rated	NULL
with	NULL
0.2	NULL
V	NULL
at	NULL
960	NULL
wF	NULL
(	NULL
Gene	NULL
Pulser	NULL
)	NULL
and	NULL
then	NULL
suspended	NULL
in	NULL
10	NULL
ml	NULL
of	NULL
RPMI	NULL
1640-10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
and	NULL
cultured	NULL
at	NULL
37Â°C	NULL
.	NULL

After	NULL
4	NULL
days	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
counted	NULL
,	NULL
and	NULL
then	NULL
assayed	NULL
.	NULL

Transfection	NULL
efficiencies	NULL
for	NULL
EBNA-2	NULL
were	NULL
J.	NULL
Viror	NULL
.	NULL

determined	NULL
in	NULL
all	NULL
experiments	NULL
by	NULL
immunofluorescence	NULL
with	NULL
an	NULL
EBNA-2-specific	NULL
monoclonal	NULL
antibody	NULL
.	NULL

Each	NULL
type	NULL
of	NULL
acute	NULL
transfection	NULL
experiment	NULL
was	NULL
repeated	NULL
at	NULL
least	NULL
three	NULL
times	NULL
.	NULL

Immunoprecipitations	NULL
.	NULL

Cells	NULL
were	NULL
pelleted	NULL
by	NULL
centrifugation	NULL
,	NULL
suspended	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
buffer	NULL
A	NULL
(	NULL
10	NULL
mM	NULL
Tris	NULL
hydro-chloride	NULL
[	NULL
pH	NULL
7.4	NULL
]	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
0.5	NULL
%	NULL
Triton	NULL
X-100	NULL
)	NULL
,	NULL
mixed	NULL
with	NULL
0.09	NULL
g	NULL
of	NULL
urea	NULL
and	NULL
4.2	NULL
pl	NULL
of	NULL
2-mercaptoethanol	NULL
,	NULL
and	NULL
vortexed	NULL
to	NULL
extract	NULL
the	NULL
detergent-soluble	NULL
and	NULL
-insoluble	NULL
LMP1	NULL
fractions	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Buffer	NULL
B	NULL
(	NULL
1	NULL
mt	NULL
)	NULL
(	NULL
10	NULL
mM	NULL
Tris	NULL
hydrochlo-ride	NULL
[	NULL
pH	NULL
7.4	NULL
]	NULL
,	NULL
250	NULL
mM	NULL
NaCl	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
1.0	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
0.1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
)	NULL
was	NULL
added	NULL
,	NULL
and	NULL
insoluble	NULL
material	NULL
was	NULL
removed	NULL
by	NULL
centrifugation	NULL
.	NULL

Equal	NULL
portions	NULL
of	NULL
the	NULL
LMP1-specific	NULL
murine	NULL
monoclonal	NULL
antibody	NULL
$	NULL
12	NULL
(	NULL
26	NULL
)	NULL
were	NULL
added	NULL
to	NULL
each	NULL
sample	NULL
and	NULL
incubated	NULL
at	NULL
4Â°C	NULL
for	NULL
1	NULL
h.	NULL
Protein	NULL
A-Sepharose	NULL
CL4B	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

was	NULL
added	NULL
,	NULL
and	NULL
samples	NULL
were	NULL
mixed	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4Â°C	NULL
.	NULL

Immunoprecipitates	NULL
were	NULL
removed	NULL
by	NULL
gentle	NULL
centrifugation	NULL
and	NULL
washed	NULL
twice	NULL
with	NULL
buffer	NULL
B.	NULL
Immunoprecipitates	NULL
were	NULL
then	NULL
suspended	NULL
in	NULL
gel	NULL
loading	NULL
buffer	NULL
,	NULL
boiled	NULL
,	NULL
and	NULL
analyzed	NULL
by	NULL
immunoblotting	NULL
.	NULL

After	NULL
LMP	NULL
immunoprecipitation	NULL
,	NULL
EBNA-2	NULL
was	NULL
immunoprecipitated	NULL
by	NULL
diluting	NULL
the	NULL
sample	NULL
with	NULL
5	NULL
ml	NULL
of	NULL
buffer	NULL
A	NULL
and	NULL
adding	NULL
the	NULL
EBNA-2-specific	NULL
murine	NULL
monoclonal	NULL
antibody	NULL
PE2	NULL
(	NULL
51	NULL
)	NULL
.	NULL

Subsequent	NULL
steps	NULL
were	NULL
as	NULL
described	NULL
above	NULL
except	NULL
that	NULL
protein	NULL
G-Sepharose	NULL
4	NULL
(	NULL
Pharmacia	NULL
,	NULL
Inc.	NULL
,	NULL
Piscataway	NULL
,	NULL
N.J.	NULL
)	NULL
was	NULL
used	NULL
to	NULL
immunoprecipitate	NULL
PE2	NULL
and	NULL
washes	NULL
were	NULL
with	NULL
buffer	NULL
A	NULL
.	NULL

All	NULL
buffers	NULL
contained	NULL
protease	NULL
inhibitors	NULL
(	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
0.7	NULL
ug	NULL
of	NULL
pepstatin	NULL
per	NULL
ml	NULL
,	NULL
0.5	NULL
ug	NULL
of	NULL
leupeptin	NULL
per	NULL
ml	NULL
,	NULL
1.0	NULL
ug	NULL
of	NULL
aprotinin	NULL
per	NULL
ml	NULL
)	NULL
.	NULL

LMP1	NULL
and	NULL
EBNA-2	NULL
were	NULL
quantitatively	NULL
immunoprecipitated	NULL
by	NULL
these	NULL
procedures	NULL
with	NULL
up	NULL
to	NULL
5	NULL
x	NULL
10Â°	NULL
EBV-infected	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
antibodies	NULL
were	NULL
in	NULL
excess	NULL
in	NULL
immunoprecipitations	NULL
from	NULL
acute	NULL
transfections	NULL
.	NULL

The	NULL
LMP1	NULL
or	NULL
EBNA-2	NULL
expression	NULL
level	NULL
in	NULL
acute	NULL
transfections	NULL
was	NULL
in	NULL
all	NULL
instances	NULL
substantially	NULL
less	NULL
than	NULL
that	NULL
of	NULL
5	NULL
x	NULL
10Â°	NULL
EBV-infected	NULL
cells	NULL
owing	NULL
to	NULL
the	NULL
fact	NULL
that	NULL
only	NULL
a	NULL
minority	NULL
of	NULL
cells	NULL
were	NULL
successfully	NULL
transfected	NULL
.	NULL

Immunoblotting	NULL
.	NULL

Cell	NULL
lysis	NULL
,	NULL
sodium	NULL
dodecyl	NULL
sulfate-poly-acrylamide	NULL
gel	NULL
electrophoresis	NULL
,	NULL
electrophoretic	NULL
transfer	NULL
to	NULL
nitrocellulose	NULL
,	NULL
and	NULL
immunoblotting	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Pooled	NULL
EBV-immune	NULL
human	NULL
sera	NULL
followed	NULL
by	NULL
*'**I-protein	NULL
A	NULL
were	NULL
used	NULL
for	NULL
detection	NULL
of	NULL
EBNAs	NULL
.	NULL

LMP	NULL
was	NULL
detected	NULL
with	NULL
the	NULL
monoclonal	NULL
antibody	NULL
$	NULL
12	NULL
(	NULL
26	NULL
)	NULL
followed	NULL
by	NULL
a	NULL
rabbit	NULL
anti-mouse	NULL
immunoglobulin	NULL
antiserum	NULL
and	NULL
**	NULL
``	NULL
I-protein	NULL
A	NULL
.	NULL

All	NULL
X-ray	NULL
film	NULL
was	NULL
preflashed	NULL
before	NULL
autoradiography	NULL
.	NULL

Immunofluorescence	NULL
.	NULL

Cells	NULL
for	NULL
immunofluorescence	NULL
were	NULL
pelleted	NULL
by	NULL
centrifugation	NULL
,	NULL
smeared	NULL
onto	NULL
microscope	NULL
slides	NULL
,	NULL
air	NULL
dried	NULL
,	NULL
and	NULL
then	NULL
fixed	NULL
for	NULL
7	NULL
min	NULL
in	NULL
ice-cold	NULL
1:1	NULL
methanol-acetone	NULL
.	NULL

Slides	NULL
were	NULL
blocked	NULL
with	NULL
10	NULL
%	NULL
goat	NULL
serum	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
for	NULL
30	NULL
min	NULL
and	NULL
stained	NULL
with	NULL
either	NULL
an	NULL
EBNA-2-specific	NULL
monoclonal	NULL
antibody	NULL
,	NULL
PE2	NULL
(	NULL
51	NULL
)	NULL
,	NULL
or	NULL
LMP1-specific	NULL
monoclonal	NULL
antibodies	NULL
CS1	NULL
to	NULL
CS4	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
M.	NULL
Rowe	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
[	NULL
37	NULL
]	NULL
)	NULL
for	NULL
1	NULL
h.	NULL
Slides	NULL
were	NULL
washed	NULL
for	NULL
30	NULL
min	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
and	NULL
then	NULL
stained	NULL
with	NULL
fluorescein	NULL
isothiocyanate-conjugated	NULL
anti-mouse	NULL
immunoglobulin	NULL
antiserum	NULL
.	NULL

EBNA-LP	NULL
immunofluorescence	NULL
was	NULL
performed	NULL
similarly	NULL
with	NULL
an	NULL
affinity-purified	NULL
monospecific	NULL
human	NULL
antiserum	NULL
against	NULL
EBNA-LP	NULL
(	NULL
49	NULL
)	NULL
followed	NULL
by	NULL
fluorescein	NULL
isothiocyanate-conjugated	NULL
anti-human	NULL
immunoglobulin	NULL
antiserum	NULL
.	NULL

Slides	NULL
were	NULL
washed	NULL
extensively	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
and	NULL
viewed	NULL
under	NULL
fluorescence	NULL
microscopy	NULL
.	NULL

CAT	NULL
assays	NULL
.	NULL

CAT	NULL
assays	NULL
were	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
12	NULL
)	NULL
except	NULL
that	NULL
cells	NULL
were	NULL
harvested	NULL
4	NULL
days	NULL
after	NULL
transfection	NULL
,	NULL
Vor	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
160	NULL
,	NULL
000	NULL
EBNA-2	NULL
TRANSACTIVATES	NULL
LMP1	NULL
3409	NULL
50	NULL
,	NULL
000	NULL
IRLl	NULL
10,000	NULL
bp	NULL
Jk	NULL
--	NULL
--	NULL
--	NULL
-A	NULL
NdEco	NULL
I	NULL
--	NULL
(	NULL
1	NULL
-512/+40	NULL
LMPCAT	NULL
P3HR-1	NULL
Del	NULL
Daudi	NULL
Del	NULL
/	NULL
--	NULL
EBNA-2	NULL
[	NULL
_________________	NULL
]	NULL
E2ai9-115	NULL
[	NULL
J	NULL
-	NULL
[	NULL
_____________	NULL
]	NULL
E24148-324	NULL
[	NULL
___	NULL
]	NULL
P	NULL
r24200-234	NULL
[	NULL
______	NULL
]	NULL
[	NULL
___	NULL
]	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Schematic	NULL
diagram	NULL
of	NULL
the	NULL
EBV	NULL
episome	NULL
from	NULL
nucleotides	NULL
160,000	NULL
to	NULL
60,000	NULL
showing	NULL
the	NULL
map	NULL
locations	NULL
of	NULL
EBNA-2	NULL
,	NULL
EBNA-LP	NULL
,	NULL
and	NULL
LMP1	NULL
.	NULL

A	NULL
portion	NULL
of	NULL
the	NULL
EBV	NULL
episome	NULL
from	NULL
nucleotide	NULL
160,000	NULL
across	NULL
the	NULL
terminal	NULL
repeats	NULL
(	NULL
TR	NULL
)	NULL
and	NULL
the	NULL
major	NULL
internal	NULL
repeat	NULL
region	NULL
(	NULL
IR1	NULL
)	NULL
to	NULL
approximately	NULL
nucleotide	NULL
60,000	NULL
is	NULL
shown	NULL
at	NULL
the	NULL
top	NULL
.	NULL

The	NULL
extent	NULL
of	NULL
the	NULL
deletions	NULL
in	NULL
P3HR-1	NULL
and	NULL
Daudi	NULL
EBV	NULL
is	NULL
represented	NULL
by	NULL
the	NULL
stippled	NULL
boxes	NULL
.	NULL

The	NULL
EBNA-2	NULL
and	NULL
the	NULL
spliced	NULL
EBNA-LP	NULL
open	NULL
reading	NULL
frames	NULL
are	NULL
represented	NULL
by	NULL
the	NULL
heavy	NULL
lines	NULL
with	NULL
arrows	NULL
.	NULL

The	NULL
deleted	NULL
regions	NULL
for	NULL
the	NULL
EBNA-2	NULL
deletion	NULL
mutants	NULL
E2d19-115	NULL
,	NULL
E2d4148-324	NULL
,	NULL
and	NULL
E2d200-234	NULL
are	NULL
illustrated	NULL
in	NULL
the	NULL
lower	NULL
right	NULL
.	NULL

The	NULL
Ny	NULL
,	NULL
,	NULL
and	NULL
NdEco	NULL
plasmids	NULL
containing	NULL
the	NULL
LMP1	NULL
gene	NULL
and	NULL
either	NULL
5.4	NULL
or	NULL
1.3	NULL
kb	NULL
of	NULL
upstream	NULL
sequences	NULL
,	NULL
respectively	NULL
,	NULL
are	NULL
shown	NULL
in	NULL
the	NULL
lower	NULL
left	NULL
.	NULL

The	NULL
-512/+40	NULL
LMPCAT	NULL
plasmid	NULL
contains	NULL
the	NULL
+40	NULL
to	NULL
-512	NULL
LMP1	NULL
upstream	NULL
sequences	NULL
linked	NULL
to	NULL
the	NULL
cat	NULL
gene	NULL
.	NULL

extracts	NULL
were	NULL
made	NULL
by	NULL
three	NULL
cycles	NULL
of	NULL
freeze-thawing	NULL
,	NULL
and	NULL
equal	NULL
portions	NULL
of	NULL
cell	NULL
lysate	NULL
were	NULL
assayed	NULL
in	NULL
30-min	NULL
enzyme	NULL
reactions	NULL
.	NULL

Simultaneous	NULL
immunofluorescence	NULL
assays	NULL
for	NULL
EBNA-2	NULL
expression	NULL
were	NULL
performed	NULL
in	NULL
all	NULL
appropriate	NULL
CAT	NULL
transfections	NULL
to	NULL
ensure	NULL
equal	NULL
and	NULL
adequate	NULL
transfection	NULL
efficiencies	NULL
.	NULL

Percent	NULL
acetylation	NULL
was	NULL
calculated	NULL
by	NULL
removing	NULL
the	NULL
nonacetylated	NULL
and	NULL
acetylated	NULL
forms	NULL
from	NULL
each	NULL
sample	NULL
and	NULL
determining	NULL
the	NULL
counts	NULL
per	NULL
minute	NULL
for	NULL
each	NULL
form	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
.	NULL

Northern	NULL
(	NULL
RNA	NULL
)	NULL
blotting	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
in	NULL
0.5	NULL
%	NULL
Nonidet	NULL
P-40-10	NULL
mM	NULL
NaCl-10	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
-3	NULL
mM	NULL
MgCl	NULL
.	NULL

Nuclei	NULL
were	NULL
separated	NULL
by	NULL
centrifugation	NULL
.	NULL

The	NULL
cytoplasmic	NULL
fraction	NULL
was	NULL
adjusted	NULL
to	NULL
1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
,	NULL
100	NULL
mM	NULL
Tris	NULL
,	NULL
and	NULL
0.2	NULL
M	NULL
NaCl	NULL
,	NULL
extracted	NULL
multiple	NULL
times	NULL
with	NULL
phenol	NULL
and	NULL
chloroform	NULL
,	NULL
and	NULL
ethanol	NULL
precipitated	NULL
.	NULL

Cytoplasmic	NULL
RNA	NULL
(	NULL
15	NULL
ug	NULL
)	NULL
was	NULL
separated	NULL
on	NULL
a	NULL
1	NULL
%	NULL
agarose-formaldehyde	NULL
gel	NULL
,	NULL
transferred	NULL
to	NULL
Genescreen	NULL
Plus	NULL
(	NULL
Amersham	NULL
Corp.	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
III	NULL
.	NULL
)	NULL

,	NULL
and	NULL
hybridized	NULL
with	NULL
randomly	NULL
primed	NULL
*Â°P-labeled	NULL
probes	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

RESULTS	NULL
EBNA-2	NULL
induces	NULL
LMP1	NULL
in	NULL
Daudi	NULL
and	NULL
P3HR-1-infected	NULL
cells	NULL
,	NULL
while	NULL
EBNA-LP	NULL
has	NULL
no	NULL
effect	NULL
.	NULL

P3HR-1	NULL
and	NULL
Daudi	NULL
EBV	NULL
are	NULL
notable	NULL
for	NULL
their	NULL
deletion	NULL
of	NULL
a	NULL
DNA	NULL
fragment	NULL
which	NULL
encodes	NULL
EBNA-2	NULL
and	NULL
the	NULL
two	NULL
3	NULL
'	NULL
unique	NULL
exons	NULL
of	NULL
EBNA-LP	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
(	NULL
4	NULL
,	NULL
15	NULL
,	NULL
16	NULL
,	NULL
19	NULL
,	NULL
22	NULL
,	NULL
34	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
LMP1	NULL
regulatory	NULL
and	NULL
coding	NULL
regions	NULL
are	NULL
more	NULL
than	NULL
50	NULL
kilobases	NULL
(	NULL
kb	NULL
)	NULL
5	NULL
'	NULL
to	NULL
this	NULL
deletion	NULL
,	NULL
LMP	NULL
expression	NULL
in	NULL
the	NULL
P3HR-1	NULL
cell	NULL
line	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
was	NULL
markedly	NULL
reduced	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
an	NULL
EBV-immortalized	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
,	NULL
IB4	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
and	NULL
was	NULL
undetectable	NULL
in	NULL
the	NULL
Daudi	NULL
cell	NULL
line	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
(	NULL
14	NULL
)	NULL
by	NULL
immunoblotting	NULL
.	NULL

EBV-negative	NULL
BL30	NULL
and	NULL
BL41	NULL
cells	NULL
stably	NULL
infected	NULL
with	NULL
P3HR-1	NULL
EBV	NULL
also	NULL
expressed	NULL
little	NULL
,	NULL
if	NULL
any	NULL
,	NULL
LMP1	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
11	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
identical	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
prototype	NULL
B95-8	NULL
EBV	NULL
expressed	NULL
high	NULL
levels	NULL
of	NULL
LMP1	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
10	NULL
)	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
EBNA-2	NULL
IB4	NULL
Louckes	NULL
P3HR-1	NULL
Daudi	NULL
BL30	NULL
BL30/B95-8	NULL
BL30/P3HR-1	NULL
1B4	NULL
BL41	NULL
BL41/B95-8	NULL
BL41/P3HR-1	NULL
66-	NULL
*	NULL
r	NULL
a	NULL
45	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

LMP1	NULL
immunoblot	NULL
of	NULL
P3HR-1	NULL
cells	NULL
,	NULL
Daudi	NULL
cells	NULL
,	NULL
and	NULL
P3HR-1-	NULL
or	NULL
B95-8	NULL
EBV-infected	NULL
BL30	NULL
or	NULL
BL41	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cells	NULL
.	NULL

Protein	NULL
extracts	NULL
from	NULL
2.5	NULL
x	NULL
10Â°	NULL
cells	NULL
were	NULL
loaded	NULL
into	NULL
each	NULL
lane	NULL
,	NULL
and	NULL
immunoblots	NULL
were	NULL
probed	NULL
with	NULL
the	NULL
LMP1-specific	NULL
monoclonal	NULL
antibody	NULL
S12	NULL
.	NULL

Molecular	NULL
mass	NULL
markers	NULL
in	NULL
kilodaltons	NULL
are	NULL
shown	NULL
.	NULL

Faint	NULL
bands	NULL
below	NULL
the	NULL
60-kDa	NULL
LMP1	NULL
represent	NULL
degradation	NULL
products	NULL
.	NULL

3410	NULL
WANG	NULL
ET	NULL
AL	NULL
.	NULL

or	NULL
a	NULL
complete	NULL
EBNA-LP	NULL
may	NULL
be	NULL
required	NULL
for	NULL
high-level	NULL
LMP	NULL
]	NULL
expression	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
role	NULL
of	NULL
the	NULL
EBNA-2	NULL
and	NULL
EBNA-LP	NULL
deletion	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
acute	NULL
effect	NULL
of	NULL
EBNA-2	NULL
and	NULL
EBNA-LP	NULL
,	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
,	NULL
on	NULL
LMP1	NULL
expression	NULL
in	NULL
P3HR-l-infected	NULL
or	NULL
Daudi	NULL
lymphoma	NULL
cells	NULL
.	NULL

The	NULL
EBV	NULL
type	NULL
1	NULL
or	NULL
type	NULL
2	NULL
EBNA-2	NULL
open	NULL
reading	NULL
frames	NULL
were	NULL
expressed	NULL
under	NULL
control	NULL
of	NULL
the	NULL
early	NULL
SV40	NULL
promoter	NULL
(	NULL
SV-EBINAZ	NULL
or	NULL
SV-EB2NA2	NULL
)	NULL
or	NULL
under	NULL
control	NULL
of	NULL
the	NULL
MuLV	NULL
LTR	NULL
(	NULL
LTR-EBINAZ	NULL
or	NULL
LTR-EB2NA2	NULL
)	NULL
.	NULL

EBNA-LP	NULL
was	NULL
expressed	NULL
from	NULL
the	NULL
bicistronic	NULL
T6S5	NULL
cDNA	NULL
(	NULL
LTR-ELP	NULL
)	NULL
or	NULL
the	NULL
monocistronic	NULL
EBNA-LP	NULL
open	NULL
reading	NULL
frame	NULL
(	NULL
pZip-ELP	NULL
)	NULL
under	NULL
control	NULL
of	NULL
the	NULL
MuLV	NULL
LTR	NULL
.	NULL

Although	NULL
the	NULL
T6S	NULL
cDNA	NULL
contains	NULL
the	NULL
EBNA-2	NULL
open	NULL
reading	NULL
frame	NULL
after	NULL
the	NULL
EBNA-LP	NULL
open	NULL
reading	NULL
frame	NULL
,	NULL
only	NULL
EBNA-LP	NULL
is	NULL
expressed	NULL
in	NULL
detectable	NULL
levels	NULL
in	NULL
B-lymphoma	NULL
cells	NULL
(	NULL
47	NULL
,	NULL
48	NULL
)	NULL
.	NULL

Four	NULL
days	NULL
after	NULL
transfection	NULL
of	NULL
SV-EBINA2	NULL
or	NULL
SV-EB2NA2	NULL
into	NULL
BL30/P3HR-1	NULL
cells	NULL
,	NULL
immunofluorescent	NULL
staining	NULL
for	NULL
EBNA-2	NULL
revealed	NULL
speckled	NULL
nuclear	NULL
staining	NULL
with	NULL
nucleolar	NULL
sparing	NULL
characteristic	NULL
of	NULL
EBNA-2	NULL
in	NULL
2	NULL
to	NULL
8	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

There	NULL
was	NULL
an	NULL
equal	NULL
distribution	NULL
of	NULL
cells	NULL
which	NULL
stained	NULL
less	NULL
,	NULL
equally	NULL
,	NULL
or	NULL
more	NULL
intensely	NULL
than	NULL
an	NULL
EBV-infected	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
control	NULL
.	NULL

Immunofiu-orescent	NULL
staining	NULL
for	NULL
LMP	NULL
revealed	NULL
bright	NULL
membrane-staining	NULL
cells	NULL
when	NULL
BL30/P3HR-1	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
SV-EBINA2	NULL
or	NULL
SV-EB2NA2	NULL
but	NULL
no	NULL
bright	NULL
membrane-staining	NULL
cells	NULL
in	NULL
BL30/P3HR-1	NULL
cells	NULL
transfected	NULL
with	NULL
vector	NULL
control	NULL
DNA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
LMP1-staining	NULL
cells	NULL
was	NULL
always	NULL
slightly	NULL
lower	NULL
than	NULL
the	NULL
percentage	NULL
of	NULL
EBNA-2-positive	NULL
cells	NULL
,	NULL
probably	NULL
because	NULL
of	NULL
the	NULL
easier	NULL
discrimination	NULL
of	NULL
low-level	NULL
nuclear	NULL
fluorescence	NULL
.	NULL

Identical	NULL
experiments	NULL
with	NULL
P3HR-1	NULL
or	NULL
Daudi	NULL
cells	NULL
revealed	NULL
similar	NULL
results	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

LMP1	NULL
expression	NULL
in	NULL
transfected	NULL
BL30/P3HR-1	NULL
and	NULL
Daudi	NULL
cells	NULL
was	NULL
also	NULL
quantitatively	NULL
assayed	NULL
by	NULL
sequential	NULL
immunoprecipitation	NULL
and	NULL
immunoblotting	NULL
.	NULL

LMP	NULL
was	NULL
readily	NULL
detectable	NULL
in	NULL
immunoprecipitates	NULL
from	NULL
BL30/P3HR-1	NULL
cells	NULL
transfected	NULL
with	NULL
either	NULL
SV-EBINA2	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
or	NULL
SV-EB2NA-2	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Little	NULL
or	NULL
no	NULL
LMP	NULL
was	NULL
detected	NULL
in	NULL
immunoprecipitates	NULL
from	NULL
vector	NULL
control-transfected	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
an	NULL
equivalent	NULL
number	NULL
of	NULL
nontransfected	NULL
BL30/P3HR-1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

The	NULL
50-and	NULL
54-kilodalton	NULL
(	NULL
kDa	NULL
)	NULL
proteins	NULL
are	NULL
from	NULL
the	NULL
immunopre-cipitating	NULL
$	NULL
12	NULL
monoclonal	NULL
antibody	NULL
,	NULL
which	NULL
is	NULL
detected	NULL
in	NULL
the	NULL
subsequent	NULL
immunoblots	NULL
by	NULL
the	NULL
secondary	NULL
rabbit	NULL
antiserum	NULL
against	NULL
mouse	NULL
immunoglobulin	NULL
.	NULL

LMP1	NULL
immunoprecipitation	NULL
from	NULL
5	NULL
x	NULL
10	NULL
%	NULL
IB4	NULL
cells	NULL
mixed	NULL
with	NULL
nontransfected	NULL
BL30/	NULL
P3HR-1	NULL
cells	NULL
was	NULL
a	NULL
control	NULL
for	NULL
the	NULL
immunoprecipitation	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

Recombinant	NULL
MuLV	NULL
EBINA-2	NULL
or	NULL
EB2NA-2	NULL
expression	NULL
vectors	NULL
also	NULL
induced	NULL
LMP1	NULL
expression	NULL
4	NULL
days	NULL
after	NULL
transfection	NULL
into	NULL
BL3O0/P3HR-1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
vector	NULL
containing	NULL
the	NULL
EBNA-LP	NULL
and	NULL
EBNA-2	NULL
bicistronic	NULL
cDNA	NULL
(	NULL
LTR-ELP	NULL
)	NULL
did	NULL
not	NULL
induce	NULL
LMP1	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Acute	NULL
EBNA-LP	NULL
expression	NULL
was	NULL
not	NULL
assayed	NULL
in	NULL
these	NULL
experiments	NULL
since	NULL
BL30/P3HR-1	NULL
cells	NULL
already	NULL
express	NULL
a	NULL
truncated	NULL
,	NULL
serologically	NULL
reactive	NULL
EBNA-LP	NULL
(	NULL
49	NULL
;	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
control	NULL
experiments	NULL
in	NULL
EBV-negative	NULL
BJAB	NULL
cells	NULL
,	NULL
the	NULL
EBNA-LP	NULL
expression	NULL
vectors	NULL
(	NULL
LTR-ELP	NULL
and	NULL
pZip-ELP	NULL
)	NULL
acutely	NULL
ex-press	NULL
,	NULL
EBNA-LP	NULL
levels	NULL
comparable	NULL
to	NULL
those	NULL
of	NULL
an	NULL
EBV-infected	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
by	NULL
immunofluorescence	NULL
with	NULL
an	NULL
affinity-purified	NULL
monospecific	NULL
human	NULL
antiserum	NULL
to	NULL
EBNA-LP	NULL
(	NULL
49	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
acute	NULL
transfection	NULL
efficiency	NULL
of	NULL
the	NULL
EBNA-LP	NULL
and	NULL
EBNA-2	NULL
vectors	NULL
was	NULL
also	NULL
similar	NULL
.	NULL

Furthermore	NULL
,	NULL
these	NULL
EBNA-LP	NULL
expression	NULL
vectors	NULL
were	NULL
previously	NULL
shown	NULL
to	NULL
produce	NULL
appropriate	NULL
EBNA-LP	NULL
J.	NULL
ViroL	NULL
.	NULL

ï¬	NULL
4	NULL
2	NULL
r-	NULL
ri	NULL
N	NULL
1	NULL
1	NULL
~	NULL
o	NULL
ha	NULL
3	NULL
3	NULL
2	NULL
3	NULL
g	NULL
#	NULL
A	NULL
2	NULL
a	NULL
P4	NULL
ri	NULL
_	NULL
m	NULL
m	NULL
r	NULL
O	NULL
m	NULL
M	NULL
Bi	NULL
fu	NULL
a	NULL
0	NULL
M	NULL
Ho	NULL
H	NULL
4	NULL
Zs	NULL
Mo	NULL
f	NULL
1	NULL
I	NULL
1	NULL
,	NULL
6	NULL
om	NULL
so	NULL
in	NULL
1	NULL
1	NULL
K	NULL
K	NULL
m	NULL
m	NULL
h	NULL
a	NULL
a	NULL
B	NULL
EH	NULL
2	NULL
a	NULL
H	NULL
U	NULL
Ow	NULL
i	NULL
H	NULL
+1	NULL
H	NULL
M	NULL
M+	NULL
I	NULL
2	NULL
]	NULL
4	NULL
S5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
B	NULL
SGS	NULL
i	NULL
F	NULL
=	NULL
-	NULL
s	NULL
+	NULL
SV-EBLINA2	NULL
-	NULL
-o	NULL
g	NULL
o-	NULL
+	NULL
-	NULL
-	NULL
+	NULL
SV-EB2NA2	NULL
-	NULL
-	NULL
+	NULL
+	NULL
-	NULL
-o	NULL
+	NULL
pZIP	NULL
+	NULL
=	NULL
+	NULL
+	NULL
pZIP-ELP	NULL
-	NULL
+	NULL
+	NULL
+	NULL
``	NULL
LTR-ELP	NULL
=	NULL
-	NULL
+	NULL
+	NULL
O+	NULL
LMP	NULL
1	NULL
-	NULL
@	NULL
R	NULL
F	NULL
``	NULL
ms.	NULL
come	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
in	NULL
y	NULL
ls	NULL
C	NULL
5	NULL
p	NULL
:	NULL
I	NULL
m	NULL
Â§	NULL
Â§	NULL
a	NULL
a	NULL
_	NULL
m	NULL
Ff	NULL
}	NULL
C	NULL
'd	NULL
m	NULL
bou	NULL
w	NULL
)	NULL
1	NULL
1	NULL
pl	NULL
3	NULL
H	NULL
m	NULL
0	NULL
po	NULL
B	NULL
a	NULL
r	NULL
H	NULL
9	NULL
a	NULL
@	NULL
h	NULL
a	NULL
+	NULL
LMP1-	NULL
Q	NULL
wiih	NULL
aum	NULL
ssc	NULL
:	NULL
ss	NULL
1	NULL
2	NULL
3	NULL
4	NULL
s	NULL
%	NULL
7	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

LMP	NULL
]	NULL
l	NULL
immunoprecipitations	NULL
from	NULL
EBNA-2-	NULL
or	NULL
EBNA-LP-transfected	NULL
BL30/P3HR-1	NULL
cells	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
and	NULL
Daudi	NULL
cells	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Protein	NULL
extracts	NULL
from	NULL
10Â°	NULL
1B4	NULL
cells	NULL
were	NULL
loaded	NULL
into	NULL
lane	NULL
1	NULL
of	NULL
each	NULL
panel	NULL
,	NULL
and	NULL
the	NULL
remaining	NULL
lanes	NULL
all	NULL
show	NULL
LMP	NULL
]	NULL
immunoprecipitations	NULL
from	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
indicated	NULL
plasmids	NULL
.	NULL

Immunoprecipitations	NULL
from	NULL
an	NULL
equivalent	NULL
number	NULL
of	NULL
untransfected	NULL
cells	NULL
(	NULL
panel	NULL
A	NULL
,	NULL
lane	NULL
8	NULL
;	NULL
panel	NULL
B	NULL
,	NULL
lane	NULL
11	NULL
;	NULL
and	NULL
panel	NULL
C	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
or	NULL
untransfected	NULL
cells	NULL
plus	NULL
5	NULL
x	NULL
10*	NULL
IB4	NULL
cells	NULL
(	NULL
panel	NULL
A	NULL
,	NULL
lane	NULL
9	NULL
;	NULL
and	NULL
panel	NULL
C	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
are	NULL
also	NULL
shown	NULL
as	NULL
controls	NULL
.	NULL

LMP1	NULL
is	NULL
60	NULL
kDa	NULL
.	NULL

The	NULL
two	NULL
smaller	NULL
proteins	NULL
come	NULL
from	NULL
the	NULL
heavy	NULL
chain	NULL
of	NULL
the	NULL
S12	NULL
monoclonal	NULL
antibody	NULL
used	NULL
for	NULL
immunoprecipitation	NULL
which	NULL
is	NULL
detected	NULL
by	NULL
the	NULL
rabbit	NULL
anti-mouse	NULL
immunoglobulin	NULL
secondary	NULL
antibody	NULL
used	NULL
to	NULL
probe	NULL
the	NULL
immunoblot	NULL
.	NULL

levels	NULL
after	NULL
stable	NULL
transfection	NULL
into	NULL
B-lymphoma	NULL
cells	NULL
(	NULL
47	NULL
,	NULL
48	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
recombinant	NULL
constructs	NULL
were	NULL
similar	NULL
to	NULL
the	NULL
EBNA-2	NULL
expression	NULL
vectors	NULL
which	NULL
transactivated	NULL
LMP1	NULL
expression	NULL
in	NULL
these	NULL
transient	NULL
assays	NULL
.	NULL

As	NULL
was	NULL
previously	NULL
observed	NULL
with	NULL
stable	NULL
transfection	NULL
and	NULL
expression	NULL
of	NULL
LTR-ELP	NULL
(	NULL
47	NULL
,	NULL
48	NULL
)	NULL
,	NULL
acute	NULL
LTR-ELP	NULL
transfection	NULL
resulted	NULL
in	NULL
EBNA-LP	NULL
but	NULL
no	NULL
detectable	NULL
EBNA-2	NULL
expression	NULL
by	NULL
immunofluorescence	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
EBV	NULL
type	NULL
1	NULL
or	NULL
type	NULL
2	NULL
EBNA-2	NULL
alone	NULL
induced	NULL
LMP	NULL
]	NULL
expression	NULL
in	NULL
BL30/P3HR-1	NULL
cells	NULL
,	NULL
while	NULL
EBNA-LP	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

EB2ZNA-2	NULL
consistently	NULL
induced	NULL
as	NULL
much	NULL
or	NULL
more	NULL
LMP1	NULL
than	NULL
did	NULL
EBINA-2	NULL
,	NULL
perhaps	NULL
in	NULL
part	NULL
because	NULL
of	NULL
a	NULL
slightly	NULL
higher	NULL
percentage	NULL
of	NULL
EB2NA-2	NULL
expression	NULL
.	NULL

Acute	NULL
EBNA-2	NULL
transactivation	NULL
of	NULL
LMP1	NULL
could	NULL
also	NULL
be	NULL
demonstrated	NULL
in	NULL
the	NULL
Daudi	NULL
cell	NULL
line	NULL
.	NULL

Transfection	NULL
of	NULL
SV-EBINA2	NULL
or	NULL
SV-EB2NA2	NULL
into	NULL
Daudi	NULL
cells	NULL
induced	NULL
LMPI1	NULL
which	NULL
was	NULL
slightly	NULL
smaller	NULL
than	NULL
the	NULL
B95-8	NULL
EBV	NULL
LMPI1	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
versus	NULL
lanes	NULL
1	NULL
and	NULL
7	NULL
)	NULL
.	NULL

The	NULL
relatively	NULL
low	NULL
LMP1	NULL
induction	NULL
is	NULL
due	NULL
in	NULL
part	NULL
to	NULL
a	NULL
1	NULL
to	NULL
2	NULL
%	NULL
Daudi	NULL
transfection	NULL
efficiency	NULL
as	NULL
determined	NULL
by	NULL
EBNA-2	NULL
immunofluorescence	NULL
.	NULL

VoL	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
a	NULL
c	NULL
m	NULL
if	NULL
in	NULL
Â®	NULL
d	NULL
u	NULL
mo	NULL
m	NULL
0	NULL
~	NULL
~	NULL
x	NULL
A	NULL
3	NULL
:	NULL
a	NULL
B	NULL
a	NULL
bos	NULL
<	NULL
<	NULL
S	NULL
2	NULL
H	NULL
a	NULL
m	NULL
@	NULL
m	NULL
-	NULL
m	NULL
Fi	NULL
Ho	NULL
Â¥	NULL
-28s	NULL
28s-LMP1-	NULL
18s-	NULL
*	NULL
2	NULL
3	NULL
i	NULL
2	NULL
EBNA-2	NULL
TRANSACTIVATES	NULL
LMP1	NULL
3411	NULL
Â«	NULL
A	NULL
o	NULL
mo	NULL
O	NULL
Â«	NULL
A	NULL
N	NULL
rA	NULL
O	NULL
&	NULL
a	NULL
Â«	NULL
%	NULL
N	NULL
N	NULL
s	NULL
Â®	NULL
8d	NULL
Bd	NULL
s	NULL
Â®	NULL
Â§	NULL
&	NULL
H	NULL
--	NULL
i	NULL
<	NULL
m	NULL
om	NULL
OH	NULL
i	NULL
4	NULL
4	NULL
4	NULL
a	NULL
m	NULL
a	NULL
:	NULL
<	NULL
4	NULL
<	NULL
4	NULL
<	NULL
4	NULL
5	NULL
8	NULL
a	NULL
A	NULL
H	NULL
a	NULL
A	NULL
a	NULL
a	NULL
-28s	NULL
<	NULL
<	NULL
M	NULL
-18s	NULL
sgÂ§	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
il	NULL
12	NULL
EBNA-2	NULL
LMP1	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Northern	NULL
blots	NULL
of	NULL
P3HR-1-	NULL
or	NULL
B95-8-infected	NULL
BL41	NULL
cells	NULL
(	NULL
A	NULL
)	NULL
or	NULL
Daudi	NULL
EBINAZ	NULL
transfectants	NULL
(	NULL
B	NULL
)	NULL
.	NULL

Cytoplasmic	NULL
RNA	NULL
(	NULL
15	NULL
ug	NULL
)	NULL
was	NULL
loaded	NULL
into	NULL
each	NULL
lane	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Blot	NULL
was	NULL
hybridized	NULL
with	NULL
LMP1	NULL
and	NULL
gamma-actin	NULL
probes	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Two	NULL
clones	NULL
of	NULL
vector	NULL
control-transfected	NULL
Daudi	NULL
cells	NULL
(	NULL
DAPZ-1	NULL
,	NULL
-2	NULL
)	NULL
and	NULL
two	NULL
clones	NULL
of	NULL
pZip-EBINA2Z-transfected	NULL
Daudi	NULL
cells	NULL
(	NULL
DAEZA-1	NULL
,	NULL
-2	NULL
)	NULL
were	NULL
hybridized	NULL
with	NULL
a	NULL
probe	NULL
for	NULL
EBNA-2	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
or	NULL
a	NULL
3.0-kb	NULL
probe	NULL
for	NULL
LMP1	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

The	NULL
LMP1	NULL
probe	NULL
includes	NULL
the	NULL
entire	NULL
open	NULL
reading	NULL
frame	NULL
and	NULL
a	NULL
large	NULL
portion	NULL
of	NULL
the	NULL
3	NULL
'	NULL
untranslated	NULL
end	NULL
.	NULL

<	NULL
<	NULL
indicates	NULL
the	NULL
Daudi	NULL
LMP	NULL
mRNA	NULL
,	NULL
which	NULL
is	NULL
the	NULL
only	NULL
mRNA	NULL
detected	NULL
with	NULL
a	NULL
probe	NULL
specific	NULL
for	NULL
LMP1	NULL
derived	NULL
for	NULL
the	NULL
5	NULL
'	NULL
exon	NULL
of	NULL
the	NULL
LMP	NULL
mRNA	NULL
.	NULL

Hybridization	NULL
of	NULL
this	NULL
blot	NULL
with	NULL
an	NULL
actin	NULL
probe	NULL
demonstrated	NULL
comparable	NULL
amounts	NULL
of	NULL
RNA	NULL
in	NULL
all	NULL
lanes	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Since	NULL
both	NULL
P3HR-1	NULL
and	NULL
Daudi	NULL
EBV	NULL
lack	NULL
a	NULL
complete	NULL
EBNA-LP	NULL
as	NULL
well	NULL
as	NULL
EBNA-2	NULL
,	NULL
further	NULL
experiments	NULL
addressed	NULL
whether	NULL
a	NULL
complete	NULL
EBNA-LP	NULL
might	NULL
synergize	NULL
with	NULL
EBNA-2	NULL
to	NULL
induce	NULL
LMP1	NULL
.	NULL

As	NULL
above	NULL
,	NULL
EBNA-LP	NULL
(	NULL
pZip-ELP	NULL
or	NULL
LTR-T65	NULL
;	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lane	NULL
3	NULL
or	NULL
8	NULL
,	NULL
respectively	NULL
)	NULL
did	NULL
not	NULL
induce	NULL
LMP	NULL
in	NULL
BL30/P3HR-1	NULL
cells	NULL
,	NULL
whereas	NULL
both	NULL
SV-EBINAZ	NULL
and	NULL
SV-EB2NA2	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
induced	NULL
LMP1	NULL
expression	NULL
.	NULL

Cotransfection	NULL
of	NULL
pZip	NULL
or	NULL
LTR	NULL
EBNA-LP	NULL
expression	NULL
vectors	NULL
with	NULL
an	NULL
EBNA-2	NULL
expression	NULL
vector	NULL
did	NULL
not	NULL
increase	NULL
LMP	NULL
expression	NULL
over	NULL
that	NULL
obtained	NULL
with	NULL
EBNA-2	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lanes	NULL
4	NULL
,	NULL
5	NULL
,	NULL
9	NULL
,	NULL
and	NULL
10	NULL
versus	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
EBNA-LP	NULL
does	NULL
not	NULL
transactivate	NULL
LMP1	NULL
expression	NULL
or	NULL
modify	NULL
the	NULL
effect	NULL
of	NULL
EBNA-2	NULL
on	NULL
LMP1	NULL
expression	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
P3HR-1	NULL
or	NULL
Daudi	NULL
EBV	NULL
genomes	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
of	NULL
isogenic	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cells	NULL
infected	NULL
with	NULL
B95-8	NULL
or	NULL
P3HR-1	NULL
EBV	NULL
or	NULL
Daudi	NULL
cells	NULL
stably	NULL
transfected	NULL
with	NULL
pZip-EBINAZ	NULL
indicated	NULL
that	NULL
EBNA-2	NULL
induces	NULL
LMP1	NULL
mRNA	NULL
.	NULL

The	NULL
first	NULL
evidence	NULL
for	NULL
an	NULL
effect	NULL
at	NULL
the	NULL
mRNA	NULL
level	NULL
was	NULL
the	NULL
observation	NULL
that	NULL
BL41/P3HR-1	NULL
cells	NULL
did	NULL
not	NULL
express	NULL
detectable	NULL
LMPI1	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
or	NULL
mRNA	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
whereas	NULL
BL41/B95-8	NULL
cells	NULL
expressed	NULL
high	NULL
levels	NULL
of	NULL
both	NULL
LMPI1	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
and	NULL
mRNA	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
(	NULL
8	NULL
)	NULL
.	NULL

More	NULL
directly	NULL
,	NULL
Daudi	NULL
cells	NULL
did	NULL
not	NULL
express	NULL
LMP1	NULL
protein	NULL
or	NULL
mRNA	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lane	NULL
4	NULL
,	NULL
and	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
,	NULL
while	NULL
three	NULL
clones	NULL
derived	NULL
by	NULL
stable	NULL
transfection	NULL
of	NULL
Daudi	NULL
cells	NULL
with	NULL
pZip-EBINA2	NULL
had	NULL
detect-able	NULL
,	NULL
albeit	NULL
low	NULL
,	NULL
EBNA-2	NULL
levels	NULL
(	NULL
two	NULL
clones	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
and	NULL
LMP	NULL
mRNA	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
11	NULL
and	NULL
12	NULL
)	NULL
.	NULL

No	NULL
LMP1	NULL
protein	NULL
induction	NULL
was	NULL
detected	NULL
by	NULL
immuno-blot	NULL
,	NULL
probably	NULL
owing	NULL
to	NULL
the	NULL
low	NULL
level	NULL
of	NULL
EBNA-2	NULL
protein	NULL
expression	NULL
(	NULL
approximately	NULL
10	NULL
%	NULL
of	NULL
1B4	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
EBNA-2-transfected	NULL
Daudi	NULL
cells	NULL
had	NULL
two	NULL
messages	NULL
that	NULL
hybridized	NULL
to	NULL
an	NULL
EBNA-2	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

The	NULL
6.8-kb	NULL
mRNA	NULL
was	NULL
the	NULL
size	NULL
expected	NULL
for	NULL
a	NULL
5'-to-3	NULL
'	NULL
LTR	NULL
transcript	NULL
,	NULL
while	NULL
the	NULL
2.4-kb	NULL
mRNA	NULL
was	NULL
the	NULL
size	NULL
expected	NULL
for	NULL
a	NULL
transcript	NULL
which	NULL
is	NULL
polyadenylated	NULL
at	NULL
the	NULL
polyadenylation	NULL
site	NULL
of	NULL
the	NULL
EBNA-2	NULL
insert	NULL
.	NULL

The	NULL
LMP	NULL
probe	NULL
detected	NULL
3.0-	NULL
,	NULL
2.4-	NULL
,	NULL
and	NULL
1.0-kb	NULL
mRNAs	NULL
in	NULL
the	NULL
EBNA-2-expressing	NULL
clones	NULL
but	NULL
not	NULL
in	NULL
the	NULL
vector	NULL
control	NULL
clones	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
11	NULL
and	NULL
12	NULL
versus	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

The	NULL
2.4-	NULL
and	NULL
1.0-kb	NULL
mRNAs	NULL
likely	NULL
represent	NULL
productive	NULL
cycle	NULL
messages	NULL
(	NULL
18	NULL
)	NULL
which	NULL
map	NULL
3	NULL
'	NULL
to	NULL
LMP1	NULL
since	NULL
they	NULL
did	NULL
not	NULL
hybridize	NULL
to	NULL
a	NULL
probe	NULL
specific	NULL
for	NULL
the	NULL
5	NULL
'	NULL
part	NULL
of	NULL
the	NULL
LMP1	NULL
mRNA	NULL
.	NULL

The	NULL
5Â°	NULL
LMP1	NULL
probe	NULL
identifies	NULL
a	NULL
3.0-kb	NULL
RNA	NULL
as	NULL
the	NULL
mRNA	NULL
expressed	NULL
from	NULL
the	NULL
Daudi	NULL
LMP1	NULL
promoter	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
EBNA-2	NULL
up	NULL
regulates	NULL
LMP	NULL
mRNA	NULL
and	NULL
may	NULL
also	NULL
up	NULL
regulate	NULL
RNAs	NULL
expressed	NULL
from	NULL
this	NULL
part	NULL
of	NULL
the	NULL
genome	NULL
during	NULL
virus	NULL
replica-tion	NULL
.	NULL

EBNA-2	NULL
transactivation	NULL
of	NULL
LMP1	NULL
does	NULL
not	NULL
require	NULL
repeating	NULL
EBNA-LP	NULL
domains	NULL
or	NULL
other	NULL
EBV	NULL
proteins	NULL
.	NULL

Daudi	NULL
or	NULL
P3HR-l-infected	NULL
cells	NULL
still	NULL
express	NULL
EBNA-1	NULL
,	NULL
EBNA-3A	NULL
,	NULL
and	NULL
EBNA-3C	NULL
as	NULL
well	NULL
as	NULL
a	NULL
truncated	NULL
EBNA-LP	NULL
,	NULL
and	NULL
these	NULL
may	NULL
be	NULL
necessary	NULL
for	NULL
the	NULL
transactivation	NULL
of	NULL
LMP	NULL
by	NULL
EBNA-2	NULL
.	NULL

We	NULL
therefore	NULL
evaluated	NULL
the	NULL
effect	NULL
of	NULL
EBNA-2	NULL
on	NULL
LMPI	NULL
expression	NULL
from	NULL
a	NULL
cotransfected	NULL
EBV	NULL
DNA	NULL
fragment	NULL
in	NULL
EBV-negative	NULL
B-lymphoma	NULL
cells	NULL
.	NULL

The	NULL
B95-8	NULL
EBV	NULL
BamHI	NULL
Ny	NULL
,	NULL
,	NULL
fragment	NULL
contains	NULL
the	NULL
entire	NULL
LMP1	NULL
gene	NULL
and	NULL
approximately	NULL
5.4	NULL
kb	NULL
of	NULL
upstream	NULL
sequences	NULL
.	NULL

Transfection	NULL
of	NULL
the	NULL
BamHI	NULL
Ny	NULL
,	NULL
,	NULL
fragment	NULL
into	NULL
EBV-negative	NULL
B-lymphoma	NULL
BJAB	NULL
or	NULL
Louckes	NULL
cells	NULL
resulted	NULL
in	NULL
detectable	NULL
LMP1	NULL
expression	NULL
by	NULL
immunoprecipitation	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
14	NULL
)	NULL
.	NULL

SV-EBINA2	NULL
cotransfection	NULL
induced	NULL
more	NULL
LMP1	NULL
expression	NULL
from	NULL
the	NULL
BamHI	NULL
Ny	NULL
,	NULL
,	NULL
fragment	NULL
than	NULL
cotransfection	NULL
with	NULL
the	NULL
pSGS5	NULL
vector	NULL
control	NULL
DNA	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
15	NULL
versus	NULL
lanes	NULL
3	NULL
and	NULL
14	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
effect	NULL
was	NULL
evident	NULL
in	NULL
EBV	NULL
-negative	NULL
BL30	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
8	NULL
and	NULL
9	NULL
)	NULL
,	NULL
although	NULL
SV-EBINA2-induced	NULL
LMP1	NULL
expression	NULL
was	NULL
less	NULL
because	NULL
of	NULL
a	NULL
lower	NULL
transfection	NULL
efficiency	NULL
in	NULL
BL30	NULL
cells	NULL
.	NULL

In	NULL
each	NULL
of	NULL
these	NULL
cells	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
transactivation	NULL
approximated	NULL
that	NULL
noted	NULL
in	NULL
transient	NULL
transfection	NULL
of	NULL
the	NULL
P3HR-1-infected	NULL
B-lymphoma	NULL
cells	NULL
with	NULL
EBNA-2	NULL
alone	NULL
.	NULL

Further	NULL
,	NULL
EBNA-LP	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
5	NULL
,	NULL
10	NULL
,	NULL
and	NULL
16	NULL
)	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
EBNA-2	NULL
(	NULL
Fig	NULL
.	NULL

SA	NULL
,	NULL
lanes	NULL
6	NULL
,	NULL
11	NULL
,	NULL
and	NULL
17	NULL
)	NULL
did	NULL
not	NULL
affect	NULL
LMP1	NULL
expression	NULL
.	NULL

Thus	NULL
,	NULL
other	NULL
EBV	NULL
genes	NULL
were	NULL
not	NULL
required	NULL
for	NULL
the	NULL
effect	NULL
of	NULL
EBNA-2	NULL
on	NULL
LMP1	NULL
expression	NULL
in	NULL
EBV-negative	NULL
B-lym-	NULL
3412	NULL
WANG	NULL
ET	NULL
AL	NULL
.	NULL

+	NULL
1	NULL
+	NULL
4	NULL
+	NULL
+	NULL
i	NULL
+	NULL
1	NULL
+	NULL
+	NULL
$	NULL
4	NULL
1	NULL
+	NULL
+	NULL
+1	NULL
+	NULL
1	NULL
J.	NULL
ViroL	NULL
.	NULL

+	NULL
1+	NULL
+	NULL
1	NULL
+	NULL
l	NULL
+	NULL
+	NULL
d	NULL
+	NULL
+1	NULL
!	NULL

+	NULL
++	NULL
!	NULL

+	NULL
!	NULL

+	NULL
l	NULL
1	NULL
4+	NULL
1	NULL
+	NULL
BJAB	NULL
16	NULL
17	NULL
BL30	NULL
Louckes	NULL
SGS	NULL
+	NULL
-	NULL
+	NULL
SV-EBINAZ	NULL
-	NULL
O+	NULL
-	NULL
+	NULL
NdECO	NULL
=	NULL
=	NULL
+	NULL
+	NULL
``	NULL
tiet	NULL
+	NULL
+	NULL
Â«	NULL
mm	NULL
sume	NULL
10	NULL
11	NULL
,	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
18	NULL
19	NULL
Louckes	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

LMP1	NULL
immunoprecipitations	NULL
from	NULL
EBV-negative	NULL
B-lymphoma	NULL
cells	NULL
(	NULL
BJAB	NULL
,	NULL
BL30	NULL
,	NULL
or	NULL
Louckes	NULL
)	NULL
cotransfected	NULL
with	NULL
EBNA-2	NULL
or	NULL
EBNA-LP	NULL
and	NULL
the	NULL
BamHI	NULL
Ny	NULL
,	NULL
.	NULL

,	NULL
genomic	NULL
LMP	NULL
DNA	NULL
.	NULL

Protein	NULL
extracts	NULL
from	NULL
10Â°	NULL
IB4	NULL
(	NULL
LMP1-positive	NULL
)	NULL
cells	NULL
are	NULL
shown	NULL
in	NULL
panel	NULL
A	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
7	NULL
,	NULL
and	NULL
in	NULL
panel	NULL
B	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
12	NULL
.	NULL

Protein	NULL
extracts	NULL
from	NULL
10Â°	NULL
BJAB	NULL
or	NULL
Louckes	NULL
cells	NULL
(	NULL
LMP1	NULL
negative	NULL
)	NULL
are	NULL
shown	NULL
in	NULL
panel	NULL
A	NULL
,	NULL
lane	NULL
2	NULL
,	NULL
and	NULL
panel	NULL
B	NULL
,	NULL
lane	NULL
13	NULL
.	NULL

Immunoprecipitations	NULL
from	NULL
equivalent	NULL
numbers	NULL
of	NULL
untransfected	NULL
B-lymphoma	NULL
cells	NULL
(	NULL
panel	NULL
A	NULL
,	NULL
lanes	NULL
12	NULL
and	NULL
18	NULL
;	NULL
panel	NULL
B	NULL
,	NULL
lanes	NULL
10	NULL
and	NULL
18	NULL
)	NULL
or	NULL
untransfected	NULL
cells	NULL
plus	NULL
10Â°	NULL
IB4	NULL
cells	NULL
(	NULL
panel	NULL
A	NULL
,	NULL
lanes	NULL
13	NULL
and	NULL
19	NULL
;	NULL
panel	NULL
B	NULL
,	NULL
lanes	NULL
11	NULL
and	NULL
19	NULL
)	NULL
are	NULL
shown	NULL
as	NULL
controls	NULL
.	NULL

Plasmid	NULL
DNAs	NULL
transfected	NULL
into	NULL
the	NULL
B-lymphoma	NULL
cells	NULL
analyzed	NULL
in	NULL
each	NULL
lane	NULL
are	NULL
indicated	NULL
by	NULL
a	NULL
+	NULL
above	NULL
the	NULL
lane	NULL
.	NULL

phoma	NULL
cells	NULL
,	NULL
and	NULL
EBNA-LP	NULL
,	NULL
specifically	NULL
,	NULL
had	NULL
no	NULL
effect	NULL
either	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
EBNA-2	NULL
.	NULL

EBNA-2-responsive	NULL
element	NULL
is	NULL
within	NULL
+40	NULL
to	NULL
-512	NULL
relative	NULL
to	NULL
LMP1	NULL
cap	NULL
site	NULL
.	NULL

A	NULL
positive	NULL
EBNA-2	NULL
effect	NULL
on	NULL
LMPI1	NULL
expression	NULL
can	NULL
still	NULL
be	NULL
demonstrated	NULL
if	NULL
the	NULL
BamHI	NULL
Ny	NULL
,	NULL
,	NULL
fragment	NULL
is	NULL
truncated	NULL
so	NULL
that	NULL
only	NULL
1.3	NULL
kb	NULL
of	NULL
LMPI	NULL
]	NULL
upstream	NULL
sequences	NULL
remain	NULL
(	NULL
NdEco	NULL
;	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Cotransfection	NULL
of	NULL
NdEco	NULL
with	NULL
SV-EBINA2	NULL
showed	NULL
more	NULL
than	NULL
a	NULL
twofold	NULL
increase	NULL
in	NULL
LMP1	NULL
expression	NULL
compared	NULL
with	NULL
NdEco	NULL
plus	NULL
vector	NULL
control	NULL
DNA	NULL
in	NULL
BJAB	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
9	NULL
versus	NULL
lanes	NULL
6	NULL
and	NULL
8	NULL
)	NULL
and	NULL
in	NULL
Louckes	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
17	NULL
versus	NULL
lane	NULL
16	NULL
)	NULL
.	NULL

LMP1	NULL
expression	NULL
from	NULL
NdEco	NULL
was	NULL
consistently	NULL
higher	NULL
than	NULL
from	NULL
the	NULL
longer	NULL
BamHI	NULL
Ny	NULL
,	NULL
,	NULL
fragment	NULL
by	NULL
immunoprecipitation	NULL
and	NULL
immunofluorescence	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
6	NULL
versus	NULL
lane	NULL
2	NULL
and	NULL
lane	NULL
16	NULL
versus	NULL
lane	NULL
14	NULL
;	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
effect	NULL
may	NULL
be	NULL
due	NULL
in	NULL
part	NULL
to	NULL
the	NULL
absence	NULL
of	NULL
inhibitory	NULL
sequences	NULL
between	NULL
-1280	NULL
and	NULL
-2350	NULL
defined	NULL
by	NULL
previous	NULL
CAT	NULL
analysis	NULL
of	NULL
LMP	NULL
]	NULL
upstream	NULL
sequences	NULL
in	NULL
EBV-infected	NULL
cells	NULL
(	NULL
11	NULL
)	NULL
or	NULL
due	NULL
to	NULL
increased	NULL
transfection	NULL
efficiency	NULL
from	NULL
the	NULL
slightly	NULL
smaller	NULL
NdEco	NULL
plasmid	NULL
.	NULL

To	NULL
further	NULL
define	NULL
the	NULL
EBNA-2-responsive	NULL
element	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
EBNA-2	NULL
responsiveness	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
cat	NULL
)	NULL
under	NULL
control	NULL
of	NULL
the	NULL
-512	NULL
to	NULL
+40	NULL
LMP1	NULL
upstream	NULL
sequences	NULL
(	NULL
-512/+40	NULL
LMPCAT	NULL
)	NULL
.	NULL

These	NULL
sequences	NULL
contain	NULL
an	NULL
element	NULL
that	NULL
is	NULL
more	NULL
active	NULL
in	NULL
B95-8	NULL
EBV-infected	NULL
cells	NULL
than	NULL
in	NULL
P3HR-1	NULL
EBV-infected	NULL
cells	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Cotransfection	NULL
of	NULL
EBINA-2-expressing	NULL
plasmids	NULL
versus	NULL
vector	NULL
control	NULL
plasmids	NULL
induced	NULL
at	NULL
least	NULL
fourfold-increased	NULL
CAT	NULL
expression	NULL
from	NULL
-512/+40	NULL
LMPCAT	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

The	NULL
-512/+40	NULL
LMPCAT	NULL
plasmid	NULL
was	NULL
responsive	NULL
to	NULL
cotransfection	NULL
with	NULL
SV-EBINA2	NULL
or	NULL
pZip-EBINA2	NULL
as	NULL
opposed	NULL
to	NULL
cotransfection	NULL
with	NULL
vector	NULL
control	NULL
DNA	NULL
into	NULL
BL30/P3HR-1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

EBINA-2	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
expression	NULL
from	NULL
the	NULL
promoterless	NULL
pCAT	NULL
or	NULL
SV40	NULL
promoter-driven	NULL
pSV2CAT	NULL
controls	NULL
.	NULL

Al	NULL
though	NULL
slight	NULL
increases	NULL
in	NULL
pSV2CAT	NULL
activity	NULL
were	NULL
occasionally	NULL
observed	NULL
in	NULL
EBNA-2	NULL
versus	NULL
vector	NULL
control	NULL
cotransfec-tions	NULL
,	NULL
slight	NULL
decreases	NULL
with	NULL
EBNA-2	NULL
and	NULL
pSV2CAT	NULL
cotransfections	NULL
were	NULL
equally	NULL
as	NULL
frequent	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
EBNA-2	NULL
consistently	NULL
increased	NULL
-512/+40	NULL
LMPCAT	NULL
activ-ity	NULL
,	NULL
by	NULL
as	NULL
much	NULL
as	NULL
15-fold	NULL
.	NULL

The	NULL
positive	NULL
EBNA-2	NULL
effect	NULL
on	NULL
-512/+40	NULL
LMPCAT	NULL
also	NULL
did	NULL
not	NULL
require	NULL
expression	NULL
of	NULL
other	NULL
EBV	NULL
genes	NULL
since	NULL
similar	NULL
results	NULL
could	NULL
be	NULL
obtained	NULL
in	NULL
the	NULL
EBV-negative	NULL
cell	NULL
line	NULL
Louckes	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

EBNA-2	NULL
effect	NULL
on	NULL
LMP1	NULL
expression	NULL
is	NULL
human	NULL
B	NULL
lymphocyte	NULL
specific	NULL
.	NULL

Similar	NULL
experiments	NULL
were	NULL
performed	NULL
in	NULL
cell	NULL
lines	NULL
other	NULL
than	NULL
human	NULL
B	NULL
lymphomas	NULL
to	NULL
assess	NULL
the	NULL
species	NULL
and	NULL
tissue	NULL
specificity	NULL
of	NULL
the	NULL
EBNA-2	NULL
effect	NULL
.	NULL

No	NULL
EBNA-2	NULL
enhancement	NULL
of	NULL
LMP1	NULL
expression	NULL
was	NULL
observed	NULL
in	NULL
a	NULL
human	NULL
T-cell-lymphotropic	NULL
virus	NULL
type	NULL
I-transformed	NULL
human	NULL
T-cell	NULL
line	NULL
(	NULL
MT-2	NULL
)	NULL
,	NULL
the	NULL
HeLa	NULL
cell	NULL
line	NULL
,	NULL
or	NULL
in	NULL
two	NULL
mouse	NULL
B-cell	NULL
lines	NULL
(	NULL
A20	NULL
and	NULL
M12	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

There	NULL
was	NULL
basal	NULL
LMP1	NULL
expression	NULL
from	NULL
transfected	NULL
BamHI	NULL
Ny	NULL
,	NULL
,	NULL
or	NULL
NdEco	NULL
in	NULL
all	NULL
cell	NULL
lines	NULL
as	NULL
observed	NULL
in	NULL
the	NULL
EBV-negative	NULL
B-lymphoma	NULL
cell	NULL
lines	NULL
and	NULL
EBNA-2	NULL
expression	NULL
as	NULL
high	NULL
as	NULL
30	NULL
%	NULL
in	NULL
HeLa	NULL
cells	NULL
as	NULL
positive	NULL
controls	NULL
for	NULL
transfection	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
an	NULL
EBNA-2	NULL
effect	NULL
in	NULL
these	NULL
cell	NULL
lines	NULL
suggests	NULL
that	NULL
a	NULL
human	NULL
B-lympho-cyte-specific	NULL
factor	NULL
is	NULL
required	NULL
for	NULL
EBNA-2	NULL
transactivation	NULL
of	NULL
LMPIL	NULL
.	NULL

EBNA-2	NULL
mutants	NULL
unable	NULL
to	NULL
transactivate	NULL
LMP	NULL
]	NULL
are	NULL
growth	NULL
transformation	NULL
incompetent	NULL
.	NULL

Recent	NULL
genetic	NULL
experiments	NULL
have	NULL
begun	NULL
to	NULL
define	NULL
EBNA-2	NULL
domains	NULL
nonessential	NULL
(	NULL
amino	NULL
acids	NULL
200	NULL
to	NULL
234	NULL
)	NULL
or	NULL
essential	NULL
(	NULL
amino	NULL
acids	NULL
19	NULL
to	NULL
115	NULL
or	NULL
148	NULL
to	NULL
324	NULL
)	NULL
for	NULL
B-lymphocyte	NULL
growth	NULL
transformation	NULL
(	NULL
7	NULL
;	NULL
J.	NULL
Cohen	NULL
,	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

Acute	NULL
transfection	NULL
of	NULL
pZip-EBINA2	NULL
,	NULL
pZip-EB2NA2	NULL
,	NULL
or	NULL
pZip-E2d200-234	NULL
into	NULL
BL30/P3HR-1	NULL
cells	NULL
induced	NULL
LMP1	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
lanes	NULL
4	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
and	NULL
10	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
pZip-E2d19-115	NULL
or	NULL
pZip-E2d148-324	NULL
deletion	NULL
mutants	NULL
did	NULL
not	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
lanes	NULL
8	NULL
and	NULL
9	NULL
)	NULL
.	NULL

By	NULL
EBNA-2	NULL
SV-EBLNA2	NULL
N	NULL
SV-EBINAZ	NULL
B	NULL
pZIP-EBINA2	NULL
SV-EBLNAZ	NULL
Â¢	NULL
48	NULL
0	NULL
0	NULL
-=	NULL
00	NULL
#	NULL
0	NULL
Â°	NULL
-	NULL
0	NULL
G0	NULL
B	NULL
_	NULL
peat	NULL
_	NULL
pSVv2caAT	NULL
V-EBINAZ	NULL
V-EBINA2	NULL
X	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

CAT	NULL
assays	NULL
of	NULL
LMP	NULL
promoter	NULL
activity	NULL
with	NULL
or	NULL
without	NULL
EBNA-2	NULL
in	NULL
BL30/P3HR-1	NULL
(	NULL
A	NULL
)	NULL
and	NULL
Louckes	NULL
(	NULL
B	NULL
)	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
cotransfected	NULL
with	NULL
vector	NULL
control	NULL
(	NULL
SGS	NULL
,	NULL
pZip	NULL
)	NULL
or	NULL
EBNA-2	NULL
(	NULL
SV-EBINA2	NULL
,	NULL
pZip-EBINA2	NULL
)	NULL
without	NULL
promoter	NULL
(	NULL
pCAT	NULL
)	NULL
,	NULL
with	NULL
SV40	NULL
promoter	NULL
(	NULL
pSV2CAT	NULL
)	NULL
,	NULL
or	NULL
with	NULL
-512/+40	NULL
LMP	NULL
]	NULL
promoter	NULL
(	NULL
-512/	NULL
+40	NULL
LMPCAT	NULL
)	NULL
CAT	NULL
reporter	NULL
constructs	NULL
indicated	NULL
above	NULL
each	NULL
lane	NULL
.	NULL

The	NULL
percent	NULL
acetylation	NULL
in	NULL
panel	NULL
A	NULL
was	NULL
0.7	NULL
and	NULL
0.7	NULL
%	NULL
for	NULL
pCAT	NULL
,	NULL
96.6	NULL
and	NULL
82.5	NULL
%	NULL
for	NULL
pSV2CAT	NULL
,	NULL
and	NULL
1.6	NULL
and	NULL
22.1	NULL
%	NULL
for	NULL
-512/+40	NULL
LMPCAT	NULL
when	NULL
cotransfected	NULL
with	NULL
SGS	NULL
and	NULL
SV-EBINA2	NULL
,	NULL
respectively	NULL
.	NULL

When	NULL
cotransfected	NULL
with	NULL
pZip	NULL
and	NULL
pZip-EBINA2	NULL
in	NULL
panel	NULL
A	NULL
,	NULL
the	NULL
percent	NULL
acetylation	NULL
was	NULL
0.9	NULL
and	NULL
1.3	NULL
%	NULL
for	NULL
pCAT	NULL
,	NULL
72.8	NULL
and	NULL
96	NULL
%	NULL
for	NULL
pSV2CAT	NULL
,	NULL
and	NULL
3.0	NULL
and	NULL
13.5	NULL
%	NULL
for	NULL
-512/+40	NULL
LMPCAT	NULL
,	NULL
respectively	NULL
.	NULL

In	NULL
panel	NULL
B	NULL
,	NULL
the	NULL
percent	NULL
acetylation	NULL
was	NULL
0.7	NULL
and	NULL
1.0	NULL
%	NULL
for	NULL
pCAT	NULL
,	NULL
31.0	NULL
and	NULL
48.7	NULL
%	NULL
for	NULL
pSV2CAT	NULL
,	NULL
and	NULL
3.1	NULL
and	NULL
15.9	NULL
%	NULL
for	NULL
-512/+40	NULL
LMPCAT	NULL
when	NULL
cotransfected	NULL
with	NULL
SGS	NULL
and	NULL
SV-EBINA2	NULL
,	NULL
respectively	NULL
.	NULL

immunofluorescence	NULL
,	NULL
there	NULL
was	NULL
comparable	NULL
expression	NULL
of	NULL
EBINA2Z	NULL
,	NULL
EB2ZNA2	NULL
,	NULL
EBNA-2d200-234	NULL
,	NULL
and	NULL
EBNA-2d148-324	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Although	NULL
as	NULL
many	NULL
strongly	NULL
positive	NULL
pZip-E2d19-115	NULL
cells	NULL
could	NULL
be	NULL
detected	NULL
,	NULL
lower-level	NULL
expression	NULL
was	NULL
difficult	NULL
to	NULL
evaluate	NULL
by	NULL
immunofluorescent	NULL
staining	NULL
because	NULL
of	NULL
its	NULL
diffuse	NULL
nuclear	NULL
pattern	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
comparable	NULL
levels	NULL
were	NULL
expressed	NULL
from	NULL
the	NULL
EBNA-2	NULL
deletion	NULL
mutant	NULL
constructs	NULL
,	NULL
we	NULL
immunoprecipitated	NULL
EBNA-2	NULL
from	NULL
the	NULL
acute	NULL
transfections	NULL
sequentially	NULL
after	NULL
LMP1	NULL
.	NULL

Comparable	NULL
levels	NULL
of	NULL
the	NULL
66-kDa	NULL
EBNA-2d419-115	NULL
,	NULL
56-kDa	NULL
EBNA-2d148-324	NULL
,	NULL
and	NULL
80-kDa	NULL
EBNA-20200-234	NULL
were	NULL
detected	NULL
in	NULL
immunoprecipitations	NULL
from	NULL
the	NULL
acute	NULL
transfections	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
,	NULL
lanes	NULL
3	NULL
,	NULL
6	NULL
,	NULL
and	NULL
7	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
this	NULL
limited	NULL
deletion	NULL
analysis	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
hypothesis	NULL
that	NULL
EBNA-2	NULL
transactivation	NULL
of	NULL
LMPI1	NULL
is	NULL
essential	NULL
for	NULL
EBV	NULL
growth	NULL
transformation	NULL
.	NULL

EBNA-2	NULL
TRANSACTIVATES	NULL
LMP1	NULL
3413	NULL
To	NULL
p	NULL
wo	NULL
No	NULL
m	NULL
Ho	NULL
M	NULL
-	NULL
a	NULL
mood	NULL
|	NULL
Â§	NULL
a	NULL
%	NULL
8	NULL
-	NULL
;	NULL
I	NULL
A	NULL
3	NULL
g	NULL
2	NULL
g	NULL
{	NULL
f	NULL
f	NULL
Â§	NULL
of	NULL
2	NULL
A	NULL
Iï¬wmmmm	NULL
Ho	NULL
O	NULL
mo	NULL
Mo	NULL
m	NULL
fu-	NULL
fu	NULL
ma	NULL
1	NULL
fued	NULL
Io	NULL
%	NULL
m	NULL
sr	NULL
r	NULL
Fl	NULL
ho	NULL
Bo	NULL
k	NULL
ko	NULL
L	NULL
o	NULL
9	NULL
M	NULL
Zaki	NULL
:	NULL
fifgf	NULL
:	NULL
``	NULL
H	NULL
M	NULL
G	NULL
u	NULL
u	NULL
Mo	NULL
ho	NULL
AQ	NULL
A	NULL
Q	NULL
M	NULL
M+	NULL
MPI	NULL
â	NULL
â	NULL
``	NULL
anions	NULL
suum	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
B	NULL
9	NULL
10	NULL
.	NULL

11	NULL
12	NULL
in	NULL
a	NULL
a	NULL
lal	NULL
2	NULL
7	NULL
x	NULL
>	NULL
%	NULL
J	NULL
Â©	NULL
o	NULL
2	NULL
a	NULL
7	NULL
Â§	NULL
a	NULL
a	NULL
0	NULL
2	NULL
J	NULL
2	NULL
M	NULL
N	NULL
N	NULL
N	NULL
o	NULL
k	NULL
m	NULL
(	NULL
ARES	NULL
!	NULL

m	NULL
!	NULL

:	NULL
i	NULL
Pd	NULL
f	NULL
Bio	NULL
fr	NULL
Ho	NULL
fi	NULL
fr	NULL
4	NULL
Â§	NULL
$	NULL
1	NULL
43	NULL
t	NULL
A.	NULL
fu	NULL
Ho	NULL
M	NULL
fi	NULL
f.	NULL
g	NULL
>	NULL
>	NULL
e	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
>	NULL
>	NULL
3	NULL
am	NULL
Â»	NULL
<	NULL
<	NULL
<	NULL
<	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

LMPI1	NULL
induction	NULL
by	NULL
EBINA-2	NULL
,	NULL
EB2NA-2	NULL
,	NULL
or	NULL
EBINA-2	NULL
deletion	NULL
mutants	NULL
.	NULL

LMP1	NULL
immunoprecipitated	NULL
from	NULL
transfected	NULL
BL30/P3HR-1	NULL
cells	NULL
is	NULL
shown	NULL
in	NULL
an	NULL
immunoblot	NULL
in	NULL
panel	NULL
A	NULL
,	NULL
lanes	NULL
4	NULL
to	NULL
10	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EBNA-2	NULL
immunoprecipitations	NULL
from	NULL
the	NULL
same	NULL
samples	NULL
.	NULL

The	NULL
EBNA-2	NULL
blot	NULL
was	NULL
developed	NULL
with	NULL
EBV-immune	NULL
human	NULL
sera	NULL
which	NULL
detect	NULL
EBNAs	NULL
.	NULL

Protein	NULL
extract	NULL
from	NULL
10Â°	NULL
1B4	NULL
cells	NULL
shown	NULL
in	NULL
panel	NULL
B	NULL
,	NULL
lane	NULL
4	NULL
,	NULL
expresses	NULL
,	NULL
from	NULL
bottom	NULL
to	NULL
top	NULL
,	NULL
EBNA-1	NULL
,	NULL
EBNA-2	NULL
,	NULL
and	NULL
the	NULL
EBNA-3A	NULL
and	NULL
EBNA-3C	NULL
doublet	NULL
.	NULL

Immunoprecipitation	NULL
with	NULL
an	NULL
EBNA-2	NULL
monoclonal	NULL
antibody	NULL
detected	NULL
comparable	NULL
amounts	NULL
of	NULL
EBNA-2	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
SV-EB2NA2	NULL
(	NULL
indicated	NULL
by	NULL
>	NULL
)	NULL
,	NULL
pZip-EBINA-2	NULL
(	NULL
>	NULL
>	NULL
)	NULL
,	NULL
pZip-E2d19-115	NULL
(	NULL
>	NULL
>	NULL
>	NULL
)	NULL
,	NULL
pZip-E2d148-324	NULL
(	NULL
<	NULL
<	NULL
<	NULL
<	NULL
)	NULL
,	NULL
and	NULL
pZip-E2d200-234	NULL
(	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
)	NULL
.	NULL

Protein	NULL
size	NULL
markers	NULL
shown	NULL
by	NULL
dashes	NULL
are	NULL
92	NULL
,	NULL
66	NULL
,	NULL
and	NULL
45	NULL
kDa	NULL
.	NULL

DISCUSSION	NULL
These	NULL
experiments	NULL
are	NULL
the	NULL
first	NULL
demonstration	NULL
that	NULL
EBNA-2	NULL
is	NULL
a	NULL
necessary	NULL
and	NULL
sufficient	NULL
transactivator	NULL
of	NULL
expression	NULL
in	NULL
B	NULL
lymphocytes	NULL
.	NULL

Previous	NULL
experiments	NULL
demonstrating	NULL
normal	NULL
LMP1	NULL
expression	NULL
only	NULL
after	NULL
infection	NULL
with	NULL
EBNA-LP-	NULL
and	NULL
EBNA-2-expressing	NULL
EBV	NULL
strains	NULL
were	NULL
consistent	NULL
with	NULL
the	NULL
hypothesis	NULL
that	NULL
EBNA-2	NULL
or	NULL
EBNA-LP	NULL
affects	NULL
LMP1	NULL
expression	NULL
(	NULL
31	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
relative	NULL
contribution	NULL
of	NULL
EBNA-LP	NULL
,	NULL
EBNA-2	NULL
,	NULL
or	NULL
other	NULL
EBV	NULL
genes	NULL
to	NULL
LMP1	NULL
expression	NULL
from	NULL
these	NULL
nonisogenic	NULL
EBV	NULL
strains	NULL
could	NULL
not	NULL
be	NULL
distinguished	NULL
.	NULL

Molecular	NULL
genetic	NULL
recombinants	NULL
restoring	NULL
normal	NULL
EBNA-LP	NULL
and	NULL
EBNA-2	NULL
genes	NULL
to	NULL
the	NULL
P3HR-1	NULL
EBV	NULL
strain	NULL
more	NULL
precisely	NULL
implicated	NULL
EBNA-LP	NULL
or	NULL
EBNA-2	NULL
in	NULL
LMP1	NULL
expression	NULL
(	NULL
7	NULL
)	NULL
but	NULL
did	NULL
not	NULL
allow	NULL
for	NULL
comparison	NULL
with	NULL
nonrecombinant	NULL
viruses	NULL
or	NULL
discriminate	NULL
between	NULL
EBNA-LP	NULL
and	NULL
EBNA-2	NULL
effects	NULL
.	NULL

In	NULL
the	NULL
current	NULL
experiments	NULL
,	NULL
the	NULL
EBNA-2	NULL
open	NULL
reading	NULL
frame	NULL
expressed	NULL
under	NULL
control	NULL
of	NULL
heterolo-	NULL
3414	NULL
WANG	NULL
ET	NULL
AL	NULL
.	NULL

gous	NULL
promoters	NULL
transactivated	NULL
LMP1	NULL
from	NULL
a	NULL
small	NULL
EBV	NULL
DNA	NULL
fragment	NULL
,	NULL
indicating	NULL
that	NULL
EBNA-2	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
any	NULL
other	NULL
EBV	NULL
genes	NULL
is	NULL
a	NULL
transactivator	NULL
of	NULL
LMP1	NULL
expression	NULL
.	NULL

Two	NULL
deletions	NULL
within	NULL
the	NULL
EBNA-2	NULL
open	NULL
reading	NULL
frame	NULL
resulted	NULL
in	NULL
mutant	NULL
EBNA-2	NULL
proteins	NULL
which	NULL
did	NULL
not	NULL
transactivate	NULL
LMP1	NULL
,	NULL
confirming	NULL
the	NULL
specific	NULL
requirement	NULL
for	NULL
EBNA-2	NULL
.	NULL

Recently	NULL
,	NULL
Cordier	NULL
et	NULL
al	NULL
.	NULL

(	NULL
8	NULL
)	NULL
reported	NULL
that	NULL
stable	NULL
EBNA-2	NULL
expression	NULL
in	NULL
BL41/P3HR-1	NULL
cells	NULL
did	NULL
not	NULL
induce	NULL
LMP1	NULL
,	NULL
whereas	NULL
Abbot	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1	NULL
)	NULL
reported	NULL
that	NULL
stable	NULL
EBNA-2	NULL
expression	NULL
induced	NULL
LMPI	NULL
in	NULL
both	NULL
BL30/P3HR-1	NULL
and	NULL
BL41/	NULL
P3HR-1	NULL
cells	NULL
.	NULL

The	NULL
reason	NULL
for	NULL
this	NULL
discrepancy	NULL
is	NULL
unclear	NULL
.	NULL

Different	NULL
expression	NULL
vectors	NULL
and	NULL
different	NULL
EBNA-2	NULL
EBV	NULL
DNA	NULL
fragments	NULL
were	NULL
used	NULL
in	NULL
the	NULL
two	NULL
studies	NULL
.	NULL

Moreover	NULL
,	NULL
since	NULL
EBNA-2	NULL
and	NULL
LMP1	NULL
both	NULL
have	NULL
significant	NULL
effects	NULL
on	NULL
B-lymphocyte	NULL
activation	NULL
(	NULL
1	NULL
,	NULL
8	NULL
,	NULL
46-48	NULL
)	NULL
,	NULL
the	NULL
precise	NULL
culture	NULL
conditions	NULL
used	NULL
to	NULL
obtain	NULL
stable	NULL
EBNA-2-expressing	NULL
clones	NULL
may	NULL
select	NULL
for	NULL
or	NULL
against	NULL
high-level	NULL
EBNA-2	NULL
and	NULL
LMP1	NULL
expression	NULL
.	NULL

Our	NULL
studies	NULL
avoid	NULL
potential	NULL
bias	NULL
introduced	NULL
by	NULL
prolonged	NULL
culture	NULL
,	NULL
enable	NULL
us	NULL
to	NULL
examine	NULL
unequivocally	NULL
the	NULL
effects	NULL
of	NULL
single	NULL
EBV	NULL
genes	NULL
in	NULL
a	NULL
number	NULL
of	NULL
EBV-positive	NULL
and	NULL
-negative	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
allow	NULL
us	NULL
to	NULL
further	NULL
characterize	NULL
both	NULL
the	NULL
EBNA-2	NULL
transactivating	NULL
domains	NULL
and	NULL
the	NULL
EBNA-2-responsive	NULL
LMP1	NULL
DNA	NULL
element	NULL
.	NULL

While	NULL
a	NULL
posttranscriptional	NULL
effect	NULL
is	NULL
not	NULL
as	NULL
yet	NULL
formally	NULL
excluded	NULL
,	NULL
the	NULL
EBNA-2	NULL
effect	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
transcriptional	NULL
.	NULL

The	NULL
strongest	NULL
evidence	NULL
for	NULL
this	NULL
is	NULL
that	NULL
EBNA-2	NULL
increases	NULL
steady-state	NULL
LMP1	NULL
mRNA	NULL
levels	NULL
in	NULL
Daudi	NULL
cells	NULL
and	NULL
increases	NULL
cat	NULL
reporter	NULL
gene	NULL
expression	NULL
when	NULL
linked	NULL
to	NULL
the	NULL
-512	NULL
to	NULL
+40	NULL
LMP1	NULL
DNA	NULL
sequences	NULL
.	NULL

EBNA-2	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
cat	NULL
gene	NULL
expression	NULL
from	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
.	NULL

Therefore	NULL
,	NULL
a	NULL
putative	NULL
EBNA-2	NULL
posttranscriptional	NULL
effect	NULL
would	NULL
have	NULL
to	NULL
depend	NULL
on	NULL
recognition	NULL
of	NULL
a	NULL
cis	NULL
element	NULL
within	NULL
the	NULL
0	NULL
to	NULL
+40	NULL
LMP	NULL
]	NULL
DNA	NULL
sequence	NULL
.	NULL

Other	NULL
data	NULL
consistent	NULL
with	NULL
EBNA-2	NULL
being	NULL
a	NULL
transcriptional	NULL
transactivator	NULL
include	NULL
the	NULL
following	NULL
.	NULL

(	NULL
i	NULL
)	NULL
EBNA-2	NULL
is	NULL
tightly	NULL
localized	NULL
to	NULL
the	NULL
cell	NULL
nucleus	NULL
(	NULL
20	NULL
)	NULL
.	NULL

(	NULL
ii	NULL
)	NULL
The	NULL
tissue	NULL
and	NULL
species	NULL
specificity	NULL
of	NULL
the	NULL
effect	NULL
of	NULL
EBNA-2	NULL
on	NULL
LMP	NULL
]	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
other	NULL
viral	NULL
or	NULL
cellular	NULL
transcriptionally	NULL
active	NULL
factors	NULL
.	NULL

(	NULL
iii	NULL
)	NULL
The	NULL
low	NULL
transcriptional	NULL
rate	NULL
of	NULL
LMP	NULL
compared	NULL
with	NULL
EBNA	NULL
transcription	NULL
even	NULL
in	NULL
EBNA-2-positive	NULL
cells	NULL
and	NULL
the	NULL
relatively	NULL
high	NULL
LMP1	NULL
mRNA	NULL
levels	NULL
in	NULL
such	NULL
cells	NULL
(	NULL
40	NULL
)	NULL
indicate	NULL
that	NULL
LMP	NULL
]	NULL
expression	NULL
could	NULL
be	NULL
stringently	NULL
regulated	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
.	NULL

(	NULL
iv	NULL
)	NULL
EBNA-2	NULL
also	NULL
up	NULL
regulates	NULL
CD21	NULL
and	NULL
CD23	NULL
cellular	NULL
mRNAs	NULL
(	NULL
8	NULL
,	NULL
47	NULL
,	NULL
48	NULL
)	NULL
.	NULL

EBNA-2	NULL
can	NULL
induce	NULL
either	NULL
the	NULL
type	NULL
a	NULL
or	NULL
type	NULL
b	NULL
CD23	NULL
mRNA	NULL
,	NULL
more	NULL
compatible	NULL
with	NULL
an	NULL
EBNA-2	NULL
effect	NULL
on	NULL
a	NULL
CD23	NULL
transcriptional	NULL
enhancer	NULL
(	NULL
48	NULL
)	NULL
.	NULL

Proof	NULL
of	NULL
an	NULL
EBNA-2	NULL
transcriptional	NULL
effect	NULL
will	NULL
require	NULL
LMP1	NULL
nuclear	NULL
runon	NULL
assays	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
EBNA-2	NULL
.	NULL

Further	NULL
characterization	NULL
and	NULL
identification	NULL
of	NULL
the	NULL
EBNA-2-responsive	NULL
element	NULL
within	NULL
the	NULL
-512	NULL
to	NULL
+40	NULL
LMPL	NULL
DNA	NULL
will	NULL
also	NULL
clarify	NULL
whether	NULL
the	NULL
responsive	NULL
element	NULL
is	NULL
part	NULL
of	NULL
the	NULL
regulatory	NULL
sequences	NULL
or	NULL
the	NULL
transcript	NULL
.	NULL

It	NULL
will	NULL
be	NULL
important	NULL
to	NULL
determine	NULL
whether	NULL
EBNA-2	NULL
also	NULL
transactivates	NULL
the	NULL
expression	NULL
of	NULL
two	NULL
recently	NULL
identified	NULL
LMP	NULL
genes	NULL
,	NULL
LMP2A	NULL
and	NULL
LMP2B	NULL
(	NULL
25	NULL
)	NULL
.	NULL

LMP2A	NULL
and	NULL
LMP2B	NULL
initiate	NULL
within	NULL
3.0	NULL
kilobase	NULL
pairs	NULL
and	NULL
250	NULL
base	NULL
pairs	NULL
of	NULL
the	NULL
LMP1	NULL
transcriptional	NULL
initiation	NULL
site	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
are	NULL
transcribed	NULL
in	NULL
the	NULL
opposite	NULL
direction	NULL
from	NULL
LMPI1	NULL
(	NULL
41	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
the	NULL
LMP2B	NULL
initiation	NULL
site	NULL
is	NULL
within	NULL
the	NULL
-512/+40	NULL
LMP1	NULL
DNA	NULL
shown	NULL
to	NULL
contain	NULL
the	NULL
EBNA-2-responsive	NULL
element	NULL
.	NULL

Although	NULL
there	NULL
are	NULL
parallels	NULL
between	NULL
the	NULL
effects	NULL
of	NULL
EBNA-2	NULL
on	NULL
CD23	NULL
and	NULL
LMP1	NULL
,	NULL
there	NULL
is	NULL
a	NULL
major	NULL
difference	NULL
in	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
EBV	NULL
type	NULL
1	NULL
and	NULL
type	NULL
2	NULL
EBNA-2s	NULL
on	NULL
these	NULL
two	NULL
genes	NULL
.	NULL

In	NULL
stable	NULL
transfection	NULL
experiments	NULL
,	NULL
EBV	NULL
type	NULL
2	NULL
EBNA-2	NULL
has	NULL
much	NULL
less	NULL
effect	NULL
on	NULL
CD23	NULL
and	NULL
CD21	NULL
than	NULL
EBV	NULL
J.	NULL
Viror	NULL
.	NULL

type	NULL
1	NULL
EBNA-2	NULL
(	NULL
48	NULL
)	NULL
,	NULL
while	NULL
in	NULL
the	NULL
acute	NULL
transfection	NULL
experiments	NULL
reported	NULL
here	NULL
,	NULL
EBV	NULL
type	NULL
2	NULL
EBNA-2	NULL
had	NULL
equal	NULL
or	NULL
greater	NULL
effects	NULL
on	NULL
LMP1	NULL
transactivation	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
pathways	NULL
by	NULL
which	NULL
EBNA-2	NULL
affects	NULL
CD23	NULL
and	NULL
LMP1l	NULL
may	NULL
differ	NULL
to	NULL
some	NULL
extent	NULL
.	NULL

The	NULL
more	NULL
potent	NULL
growth	NULL
phenotype	NULL
of	NULL
type	NULL
1	NULL
versus	NULL
type	NULL
2	NULL
EBV	NULL
in	NULL
cell	NULL
transformation	NULL
(	NULL
36	NULL
)	NULL
parallels	NULL
the	NULL
more	NULL
potent	NULL
type	NULL
1	NULL
EBNA-2	NULL
effects	NULL
on	NULL
CD21	NULL
and	NULL
CD23	NULL
.	NULL

Indeed	NULL
,	NULL
B	NULL
lymphocytes	NULL
transformed	NULL
with	NULL
type	NULL
2	NULL
EBNA-2	NULL
recombinant	NULL
P3HR-1	NULL
EBV	NULL
express	NULL
less	NULL
CD23	NULL
,	NULL
grow	NULL
more	NULL
slowly	NULL
,	NULL
and	NULL
yet	NULL
express	NULL
similar	NULL
LMP1	NULL
levels	NULL
compared	NULL
with	NULL
isogenic	NULL
cells	NULL
transformed	NULL
with	NULL
type	NULL
1	NULL
EBNA-2	NULL
recombinant	NULL
P3HR-1	NULL
(	NULL
7	NULL
)	NULL
.	NULL

The	NULL
differential	NULL
effects	NULL
of	NULL
type	NULL
1	NULL
and	NULL
type	NULL
2	NULL
EBNA-2s	NULL
on	NULL
CD23	NULL
and	NULL
cell	NULL
growth	NULL
phenotype	NULL
versus	NULL
their	NULL
similar	NULL
effect	NULL
on	NULL
LMP1	NULL
indicate	NULL
that	NULL
EBNA-2	NULL
has	NULL
significant	NULL
functions	NULL
not	NULL
fully	NULL
concordant	NULL
with	NULL
LMPI1	NULL
transactivation	NULL
.	NULL

EBNA-2	NULL
could	NULL
be	NULL
similar	NULL
to	NULL
adenovirus	NULL
E1A	NULL
and	NULL
SV40	NULL
T	NULL
antigen	NULL
in	NULL
having	NULL
direct	NULL
effects	NULL
on	NULL
viral	NULL
and	NULL
cellular	NULL
gene	NULL
expression	NULL
(	NULL
see	NULL
references	NULL
24	NULL
and	NULL
30	NULL
for	NULL
reviews	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
other	NULL
effects	NULL
on	NULL
cell	NULL
growth	NULL
which	NULL
could	NULL
also	NULL
affect	NULL
gene	NULL
expression	NULL
(	NULL
10	NULL
,	NULL
50	NULL
)	NULL
.	NULL

A	NULL
molecular	NULL
genetic	NULL
dissection	NULL
of	NULL
EBNA-2	NULL
may	NULL
eventually	NULL
reveal	NULL
the	NULL
distinct	NULL
functional	NULL
domains	NULL
responsible	NULL
for	NULL
LMP1	NULL
and	NULL
cellular	NULL
gene	NULL
transactivation	NULL
suggested	NULL
by	NULL
these	NULL
data	NULL
.	NULL

In	NULL
these	NULL
preliminary	NULL
studies	NULL
,	NULL
two	NULL
deletions	NULL
within	NULL
EBNA-2	NULL
separated	NULL
by	NULL
33	NULL
amino	NULL
acids	NULL
(	NULL
E2d419-115	NULL
and	NULL
E2d4148-324	NULL
)	NULL
inactivated	NULL
LMP1	NULL
transactivation	NULL
and	NULL
also	NULL
inactivated	NULL
growth-transforming	NULL
ability	NULL
,	NULL
while	NULL
another	NULL
deletion	NULL
(	NULL
E2d4200-234	NULL
)	NULL
which	NULL
does	NULL
not	NULL
alter	NULL
LMP1	NULL
transactivation	NULL
retained	NULL
growth-transforming	NULL
capacity	NULL
.	NULL

In	NULL
light	NULL
of	NULL
the	NULL
central	NULL
role	NULL
of	NULL
LMP1	NULL
in	NULL
EBV	NULL
effects	NULL
on	NULL
B	NULL
lymphocytes	NULL
(	NULL
46	NULL
,	NULL
48	NULL
)	NULL
,	NULL
it	NULL
is	NULL
not	NULL
surprising	NULL
that	NULL
transactivation	NULL
might	NULL
be	NULL
essential	NULL
for	NULL
growth	NULL
transformation	NULL
.	NULL

However	NULL
,	NULL
EBNA-2	NULL
transactivation	NULL
of	NULL
LMP	NULL
may	NULL
not	NULL
be	NULL
sufficient	NULL
for	NULL
growth	NULL
transformation	NULL
,	NULL
and	NULL
we	NULL
may	NULL
also	NULL
expect	NULL
to	NULL
define	NULL
EBNA-2	NULL
domains	NULL
which	NULL
are	NULL
necessary	NULL
for	NULL
growth	NULL
transformation	NULL
but	NULL
are	NULL
not	NULL
necessary	NULL
for	NULL
LMPI1	NULL
transactivation	NULL
.	NULL

These	NULL
may	NULL
define	NULL
domains	NULL
important	NULL
for	NULL
interaction	NULL
with	NULL
other	NULL
cell	NULL
transcriptional	NULL
or	NULL
growth-regulatory	NULL
factors	NULL
.	NULL

A	NULL
major	NULL
component	NULL
of	NULL
the	NULL
action	NULL
of	NULL
EBNA-2	NULL
on	NULL
B	NULL
lymphocytes	NULL
is	NULL
mediated	NULL
through	NULL
LMP1	NULL
,	NULL
which	NULL
is	NULL
a	NULL
broad	NULL
effector	NULL
of	NULL
B-lymphocyte	NULL
growth	NULL
and	NULL
gene	NULL
expression	NULL
.	NULL

In	NULL
three	NULL
EBV-negative	NULL
B-lymphoma	NULL
cell	NULL
lines	NULL
,	NULL
LMPA	NULL
induces	NULL
homotypic	NULL
adhesion	NULL
associated	NULL
with	NULL
increased	NULL
expression	NULL
of	NULL
cellular	NULL
adhesion	NULL
molecules	NULL
,	NULL
characteristic	NULL
profiles	NULL
of	NULL
B-cell	NULL
activation	NULL
antigens	NULL
,	NULL
and	NULL
vimentin	NULL
expression	NULL
(	NULL
3	NULL
,	NULL
46	NULL
,	NULL
48	NULL
)	NULL
.	NULL

In	NULL
at	NULL
least	NULL
one	NULL
B-lymphoma	NULL
cell	NULL
line	NULL
,	NULL
LMP1	NULL
also	NULL
raises	NULL
the	NULL
intra-cellular	NULL
free	NULL
calcium	NULL
level	NULL
and	NULL
alters	NULL
transforming	NULL
growth	NULL
factor	NULL
beta	NULL
responsiveness	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
biological	NULL
impact	NULL
of	NULL
EBNA-2	NULL
is	NULL
amplified	NULL
by	NULL
its	NULL
transactivation	NULL
of	NULL
the	NULL
LMP1-mediated	NULL
growth	NULL
effects	NULL
.	NULL

The	NULL
EBNA-2	NULL
effect	NULL
can	NULL
be	NULL
further	NULL
amplified	NULL
by	NULL
its	NULL
synergistic	NULL
interaction	NULL
with	NULL
LMPI1	NULL
as	NULL
seen	NULL
with	NULL
CD23	NULL
induction	NULL
(	NULL
48	NULL
)	NULL
.	NULL

CD23	NULL
is	NULL
prominently	NULL
up	NULL
regulated	NULL
in	NULL
EBV	NULL
infection	NULL
.	NULL

The	NULL
type	NULL
a	NULL
CD23	NULL
mRNA	NULL
is	NULL
constitutively	NULL
expressed	NULL
in	NULL
B	NULL
lymphocytes	NULL
,	NULL
and	NULL
the	NULL
type	NULL
b	NULL
CD23	NULL
mRNA	NULL
is	NULL
preferentially	NULL
turned	NULL
on	NULL
by	NULL
LMPIL	NULL
.	NULL

EBNA-2	NULL
can	NULL
increase	NULL
either	NULL
CD23	NULL
mRNA	NULL
form	NULL
and	NULL
acts	NULL
synergistically	NULL
when	NULL
coexpressed	NULL
with	NULL
LMPI	NULL
to	NULL
induce	NULL
high-level	NULL
CD23	NULL
expression	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
LMPI1	NULL
require	NULL
expression	NULL
at	NULL
the	NULL
level	NULL
normally	NULL
found	NULL
in	NULL
latent	NULL
EBV	NULL
infection	NULL
(	NULL
46	NULL
,	NULL
48	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
EBNA-2	NULL
regulation	NULL
of	NULL
LMP1	NULL
expression	NULL
also	NULL
underscores	NULL
the	NULL
central	NULL
role	NULL
for	NULL
EBNA-2	NULL
in	NULL
EBV-induced	NULL
B-lymphocyte	NULL
growth	NULL
transformation	NULL
.	NULL

Although	NULL
EBNA-LP	NULL
did	NULL
not	NULL
have	NULL
any	NULL
direct	NULL
effects	NULL
on	NULL
LMP1	NULL
expression	NULL
in	NULL
these	NULL
experiments	NULL
,	NULL
we	NULL
can	NULL
not	NULL
rule	NULL
out	NULL
an	NULL
indirect	NULL
role	NULL
for	NULL
EBNA-LP	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
linkage	NULL
between	NULL
EBNA-LP	NULL
and	NULL
EBNA-2	NULL
in	NULL
bicistronic	NULL
mRNAs	NULL
suggests	NULL
a	NULL
Vor	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
need	NULL
for	NULL
joint	NULL
expression	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Since	NULL
we	NULL
used	NULL
heterologous	NULL
promoters	NULL
for	NULL
these	NULL
studies	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
EBNA-LP	NULL
,	NULL
or	NULL
other	NULL
viral	NULL
genes	NULL
,	NULL
affect	NULL
LMP1	NULL
expression	NULL
indirectly	NULL
through	NULL
modulation	NULL
of	NULL
EBNA-2	NULL
expression	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
David	NULL
Liebowitz	NULL
and	NULL
Clare	NULL
Sample	NULL
for	NULL
valuable	NULL
discussions	NULL
and	NULL
advice	NULL
.	NULL

This	NULL
research	NULL
was	NULL
supported	NULL
by	NULL
Public	NULL
Health	NULL
Service	NULL
grant	NULL
CA47006	NULL
from	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
.	NULL

F.W	NULL
.	NULL

and	NULL
J.I.C	NULL
.	NULL

have	NULL
fellowships	NULL
CA01395	NULL
and	NULL
CAO1417	NULL
from	NULL
the	NULL
National	NULL
Cancer	NULL
Insti-tute	NULL
,	NULL
S.T	NULL
.	NULL

is	NULL
supported	NULL
by	NULL
training	NULL
grant	NULL
T32A107061-13	NULL
from	NULL
the	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
,	NULL
M.G.K	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Life	NULL
Sciences	NULL
Research	NULL
Foundation	NULL
,	NULL
and	NULL
E.K	NULL
.	NULL

is	NULL
partially	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Sandoz	NULL
Corporation	NULL
and	NULL
the	NULL
Baxter	NULL
Foundation	NULL
.	NULL

LITERATURE	NULL
CITED	NULL
1	NULL
.	NULL

Abbot	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
K.	NULL
Cadwallader	NULL
,	NULL
A.	NULL
Ricksten	NULL
,	NULL
J.	NULL
Gordon	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
L.	NULL
Rymo	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1990	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
2	NULL
induces	NULL
expression	NULL
of	NULL
the	NULL
virus-encoded	NULL
latent	NULL
membrane	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:2126-2134	NULL
.	NULL

2	NULL
.	NULL

Baichwal	NULL
,	NULL
V.	NULL
R.	NULL
,	NULL
and	NULL
B.	NULL
Sugden	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
multiple	NULL
membrane-spanning	NULL
segments	NULL
of	NULL
the	NULL
BNLF-1	NULL
oncogene	NULL
from	NULL
Epstein-Barr	NULL
virus	NULL
are	NULL
required	NULL
for	NULL
transformation	NULL
.	NULL

Oncogene	NULL
4:67-74	NULL
.	NULL

3	NULL
.	NULL

Birkenbach	NULL
,	NULL
M.	NULL
,	NULL
D.	NULL
Liebowitz	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
J	NULL
.	NULL

Sample	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1989	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latent	NULL
infection	NULL
membrane	NULL
protein	NULL
increases	NULL
vimentin	NULL
expression	NULL
in	NULL
human	NULL
B-cell	NULL
lines	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:4079-4084	NULL
.	NULL

4	NULL
.	NULL

Bornkamm	NULL
,	NULL
G.	NULL
W.	NULL
,	NULL
J.	NULL
Hudewentz	NULL
,	NULL
U.	NULL
K.	NULL
Freese	NULL
,	NULL
and	NULL
U.	NULL
Zimber	NULL
.	NULL

1982	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
non-transforming	NULL
Epstein-Barr	NULL
virus	NULL
strain	NULL
P3HR-1	NULL
causes	NULL
fusion	NULL
of	NULL
the	NULL
large	NULL
internal	NULL
repeat	NULL
to	NULL
the	NULL
DSL	NULL
region	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

43:952-968	NULL
.	NULL

5	NULL
.	NULL

Calender	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Billaud	NULL
,	NULL
J.	NULL
P.	NULL
Aubry	NULL
,	NULL
J.	NULL
Banchereau	NULL
,	NULL
M.	NULL
Vuillame	NULL
,	NULL
and	NULL
G.	NULL
M.	NULL
Lenoir	NULL
.	NULL

1987	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
induces	NULL
expression	NULL
of	NULL
B-cell	NULL
activation	NULL
markers	NULL
on	NULL
in	NULL
vitro	NULL
infection	NULL
of	NULL
EBV-negative	NULL
B-lymphoma	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:8060-8064	NULL
.	NULL

6	NULL
.	NULL

Cleary	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
R.	NULL
F.	NULL
Dorfman	NULL
,	NULL
and	NULL
J.	NULL
Sklar	NULL
.	NULL

1986	NULL
.	NULL

Failure	NULL
in	NULL
immunological	NULL
control	NULL
of	NULL
the	NULL
virus	NULL
infection	NULL
:	NULL
post-transplant	NULL
lymphomas	NULL
,	NULL
p.	NULL
163-181	NULL
.	NULL

In	NULL
M.	NULL
A.	NULL
Epstein	NULL
and	NULL
B.	NULL
C.	NULL
Achong	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
The	NULL
Epstein-Barr	NULL
virus	NULL
:	NULL
recent	NULL
advances	NULL
.	NULL

William	NULL
Heine-mann	NULL
,	NULL
London	NULL
.	NULL

7	NULL
.	NULL

Cohen	NULL
,	NULL
J.	NULL
I.	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
J.	NULL
Mannick	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1989	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
nuclear	NULL
protein	NULL
2	NULL
is	NULL
a	NULL
key	NULL
determinant	NULL
of	NULL
lymphocyte	NULL
transformation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:9558-9562	NULL
.	NULL

8	NULL
.	NULL

Cordier	NULL
,	NULL
R.	NULL
,	NULL
A.	NULL
Calender	NULL
,	NULL
M.	NULL
Billand	NULL
,	NULL
U.	NULL
Zimber	NULL
,	NULL
G.	NULL
Rousselet	NULL
,	NULL
O.	NULL
Pavlish	NULL
,	NULL
J.	NULL
Banchereau	NULL
,	NULL
T.	NULL
Tursz	NULL
,	NULL
G.	NULL
Bornkamm	NULL
,	NULL
and	NULL
G.	NULL
M.	NULL
Lenoir	NULL
.	NULL

1990	NULL
.	NULL

Stable	NULL
transfection	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
nuclear	NULL
antigen	NULL
2	NULL
in	NULL
lymphoma	NULL
cells	NULL
containing	NULL
the	NULL
EBV	NULL
P3HR-1	NULL
genome	NULL
induces	NULL
expression	NULL
of	NULL
B-cell	NULL
activation	NULL
molecules	NULL
CD21	NULL
and	NULL
CD23	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:1002-1013	NULL
.	NULL

9	NULL
.	NULL

Dambaugh	NULL
,	NULL
T.	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
K.	NULL
Hennessy	NULL
,	NULL
E.	NULL
Woodland	NULL
,	NULL
A.	NULL
Rickinson	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1986	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
protein	NULL
2	NULL
in	NULL
rodent	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

59:453-462	NULL
.	NULL

10	NULL
.	NULL

DeCaprio	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
J.	NULL
W.	NULL
Ludlow	NULL
,	NULL
J.	NULL
Figge	NULL
,	NULL
J.	NULL
Shaw	NULL
,	NULL
C.	NULL
Huang	NULL
,	NULL
W.	NULL
Lee	NULL
,	NULL
E.	NULL
Marsilio	NULL
,	NULL
E.	NULL
Pauch	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
Livingston	NULL
.	NULL

1988	NULL
.	NULL

SV40	NULL
large	NULL
tumor	NULL
antigen	NULL
forms	NULL
a	NULL
specific	NULL
complex	NULL
with	NULL
the	NULL
product	NULL
of	NULL
the	NULL
retinoblastoma	NULL
susceptibility	NULL
gene	NULL
.	NULL

Cell	NULL
54:275-283	NULL
.	NULL

11	NULL
.	NULL

Ghosh	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1990.	NULL
cis-Acting	NULL
regulatory	NULL
elements	NULL
near	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
latent-infection	NULL
membrane	NULL
protein	NULL
transcriptional	NULL
start	NULL
site	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:1855-1858	NULL
.	NULL

12	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
L.	NULL
F.	NULL
Moffat	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyltransferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

2:1044-1051	NULL
.	NULL

13	NULL
.	NULL

Hammerschmidt	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
B.	NULL
Sugden	NULL
.	NULL

1989	NULL
.	NULL

Genetic	NULL
analysis	NULL
of	NULL
immortalizing	NULL
functions	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
in	NULL
human	NULL
B	NULL
lymphocytes	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
340:393-397	NULL
.	NULL

14	NULL
.	NULL

Hatzubai	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Anafi	NULL
,	NULL
M.	NULL
G.	NULL
Masucci	NULL
,	NULL
J.	NULL
Dillner	NULL
,	NULL
R.	NULL
A.	NULL
Lerner	NULL
,	NULL
G.	NULL
Klein	NULL
,	NULL
and	NULL
D.	NULL
Sulitzeanu	NULL
.	NULL

1987	NULL
.	NULL

Down-regulation	NULL
of	NULL
the	NULL
EBV-encoded	NULL
membrane	NULL
protein	NULL
(	NULL
LMP	NULL
)	NULL
in	NULL
Burkitt	NULL
lymphomas	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
40:358-364	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

EBNA-2	NULL
TRANSACTIVATES	NULL
LMP1	NULL
3415	NULL
Hayward	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
S.	NULL
Lazarowitz	NULL
,	NULL
and	NULL
G.	NULL
S.	NULL
Hayward	NULL
.	NULL

1982	NULL
.	NULL

Organization	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
DNA	NULL
molecule	NULL
.	NULL

II	NULL
.	NULL

Fine	NULL
mapping	NULL
of	NULL
the	NULL
boundaries	NULL
of	NULL
the	NULL
internal	NULL
repeat	NULL
cluster	NULL
of	NULL
B95-8	NULL
and	NULL
identification	NULL
of	NULL
additional	NULL
small	NULL
tandem	NULL
repeats	NULL
adjacent	NULL
to	NULL
the	NULL
HR-1	NULL
deletion	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

43:201-212	NULL
.	NULL

Heller	NULL
,	NULL
M.	NULL
,	NULL
T.	NULL
Dambaugh	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1981	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
DNA	NULL
.	NULL

IX	NULL
.	NULL

Variation	NULL
among	NULL
viral	NULL
DNAs	NULL
from	NULL
producer	NULL
and	NULL
nonproducer	NULL
infected	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

38:632-648	NULL
.	NULL

Henle	NULL
,	NULL
W.	NULL
,	NULL
V.	NULL
Diehl	NULL
,	NULL
G.	NULL
Kohn	NULL
,	NULL
H.	NULL
zur	NULL
Hausen	NULL
,	NULL
and	NULL
G.	NULL
Henle	NULL
.	NULL

1967	NULL
.	NULL

Herpes-type	NULL
virus	NULL
and	NULL
chromosome	NULL
marker	NULL
in	NULL
normal	NULL
leukocytes	NULL
after	NULL
growth	NULL
with	NULL
irradiated	NULL
Burkitt	NULL
cells	NULL
.	NULL

Science	NULL
157:1064-1065	NULL
.	NULL

Hudson	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
P.	NULL
J.	NULL
Farrell	NULL
,	NULL
and	NULL
B.	NULL
G.	NULL
Barrell	NULL
.	NULL

1985	NULL
.	NULL

Two	NULL
related	NULL
but	NULL
differentially	NULL
expressed	NULL
potential	NULL
membrane	NULL
proteins	NULL
encoded	NULL
by	NULL
the	NULL
EcoRI	NULL
Dhet	NULL
region	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
B95-8	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

53:528-535	NULL
.	NULL

Jones	NULL
,	NULL
M.	NULL
,	NULL
L.	NULL
Foster	NULL
,	NULL
T.	NULL
Sheedy	NULL
,	NULL
and	NULL
B.	NULL
Griffin	NULL
.	NULL

1984	NULL
.	NULL

The	NULL
EB	NULL
virus	NULL
genome	NULL
in	NULL
Daudi	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cells	NULL
has	NULL
a	NULL
deletion	NULL
similar	NULL
to	NULL
that	NULL
observed	NULL
in	NULL
a	NULL
non-transforming	NULL
strain	NULL
(	NULL
P3HR-1	NULL
)	NULL
of	NULL
the	NULL
virus	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

3:813-821	NULL
.	NULL

Kieff	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
D.	NULL
Liebowitz	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
,	NULL
p.	NULL
1889-1920	NULL
.	NULL

In	NULL
B	NULL
.	NULL

Fields	NULL
and	NULL
D.	NULL
Knipe	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Virology	NULL
.	NULL

Raven	NULL
Press	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Kim	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
C.	NULL
Kanellopoulos-Langevin	NULL
,	NULL
R.	NULL
M.	NULL
Merwin	NULL
,	NULL
D.	NULL
H.	NULL
Sachs	NULL
,	NULL
and	NULL
R.	NULL
Asofsky	NULL
.	NULL

1979	NULL
.	NULL

Establishment	NULL
and	NULL
characterization	NULL
of	NULL
Balb/c	NULL
lymphoma	NULL
lines	NULL
with	NULL
B	NULL
cell	NULL
properties	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

122:549-554	NULL
.	NULL

King	NULL
,	NULL
W.	NULL
,	NULL
T.	NULL
Dambaugh	NULL
,	NULL
M.	NULL
Heller	NULL
,	NULL
J.	NULL
Dowling	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1982	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
DNA	NULL
.	NULL

XII	NULL
.	NULL

A	NULL
variable	NULL
region	NULL
of	NULL
the	NULL
EBV	NULL
genome	NULL
is	NULL
included	NULL
in	NULL
the	NULL
P3HR-1	NULL
deletion	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

43:979-986	NULL
.	NULL

Liebowitz	NULL
,	NULL
D.	NULL
,	NULL
R.	NULL
Kopan	NULL
,	NULL
E.	NULL
Fuchs	NULL
,	NULL
J	NULL
.	NULL

Sample	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
Epstein-Barr	NULL
virus	NULL
transforming	NULL
protein	NULL
associates	NULL
with	NULL
vimentin	NULL
in	NULL
lymphocytes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7:2299-2308	NULL
.	NULL

Livingston	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
and	NULL
M.	NULL
K.	NULL
Bradley	NULL
.	NULL

1987.	NULL
Review	NULL
:	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
large	NULL
T	NULL
antigen-a	NULL
lot	NULL
packed	NULL
into	NULL
a	NULL
little	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Med	NULL
.	NULL

4:63-80	NULL
.	NULL

Longnecker	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1990	NULL
.	NULL

A	NULL
second	NULL
Epstein-Barr	NULL
virus	NULL
membrane	NULL
protein	NULL
(	NULL
LMP2	NULL
)	NULL
is	NULL
expressed	NULL
in	NULL
latent	NULL
infection	NULL
and	NULL
colocalizes	NULL
with	NULL
LMP1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:2319-2326	NULL
.	NULL

Mann	NULL
,	NULL
K.	NULL
,	NULL
D.	NULL
Staunton	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Thorley-Lawson	NULL
.	NULL

1985	NULL
.	NULL

An	NULL
Epstein-Barr	NULL
virus-encoded	NULL
protein	NULL
found	NULL
in	NULL
plasma	NULL
membranes	NULL
of	NULL
transformed	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

55:233-237	NULL
.	NULL

Menezes	NULL
,	NULL
J.	NULL
,	NULL
W.	NULL
Liebold	NULL
,	NULL
G.	NULL
Klein	NULL
,	NULL
and	NULL
G.	NULL
Clements	NULL
,	NULL
1975	NULL
.	NULL

Establishment	NULL
and	NULL
characterization	NULL
of	NULL
an	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
-negative	NULL
lymphoblastoid	NULL
B	NULL
cell	NULL
line	NULL
(	NULL
BJA-B	NULL
)	NULL
from	NULL
an	NULL
exceptional	NULL
,	NULL
EBV-genome-negative	NULL
African	NULL
Burkitt	NULL
's	NULL
lym-phoma	NULL
.	NULL

Biomedicine	NULL
22:276-284	NULL
.	NULL

Miller	NULL
,	NULL
G.	NULL
,	NULL
J.	NULL
Robinson	NULL
,	NULL
L.	NULL
Herston	NULL
,	NULL
and	NULL
M.	NULL
Lipman	NULL
.	NULL

1974	NULL
.	NULL

Differences	NULL
between	NULL
laboratory	NULL
strains	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
based	NULL
on	NULL
immortalization	NULL
,	NULL
abortive	NULL
infection	NULL
and	NULL
interference	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
71:4006-4010	NULL
.	NULL

Miyoshi	NULL
,	NULL
I.	NULL
,	NULL
I.	NULL
Kubonishi	NULL
,	NULL
S.	NULL
Yoshimoto	NULL
,	NULL
T.	NULL
Akagi	NULL
,	NULL
Y.	NULL
Ohtsuki	NULL
,	NULL
Y.	NULL
Shiraishi	NULL
,	NULL
K.	NULL
Nagata	NULL
,	NULL
and	NULL
Y.	NULL
Hinuma	NULL
.	NULL

1981	NULL
.	NULL

Type	NULL
C	NULL
virus	NULL
particles	NULL
in	NULL
a	NULL
cord	NULL
T-cell	NULL
line	NULL
derived	NULL
by	NULL
co-cultivating	NULL
normal	NULL
human	NULL
cord	NULL
leukocytes	NULL
and	NULL
human	NULL
leukaemic	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
294:770-771	NULL
.	NULL

Moran	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Mathews	NULL
.	NULL

1987	NULL
.	NULL

Multiple	NULL
functional	NULL
domains	NULL
in	NULL
the	NULL
adenovirus	NULL
E1A	NULL
gene	NULL
.	NULL

Cell	NULL
48:177-178	NULL
.	NULL

Murray	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
L.	NULL
S.	NULL
Young	NULL
,	NULL
A.	NULL
Calender	NULL
,	NULL
C.	NULL
D.	NULL
Gregory	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
G.	NULL
M.	NULL
Lenoir	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1988	NULL
.	NULL

Different	NULL
patterns	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
gene	NULL
expression	NULL
and	NULL
of	NULL
cytotoxic	NULL
T-cell	NULL
recognition	NULL
in	NULL
B-cell	NULL
lines	NULL
infected	NULL
with	NULL
transforming	NULL
(	NULL
B95.8	NULL
)	NULL
or	NULL
nontransforming	NULL
(	NULL
P3HR1	NULL
)	NULL
virus	NULL
strains	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:894-901	NULL
.	NULL

Pope	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
M.	NULL
K.	NULL
Horne	NULL
,	NULL
and	NULL
W.	NULL
Scott	NULL
.	NULL

1968	NULL
.	NULL

Transformation	NULL
of	NULL
fetal	NULL
human	NULL
leukocytes	NULL
in	NULL
vitro	NULL
by	NULL
filtrates	NULL
of	NULL
a	NULL
human	NULL
leukaemic	NULL
cell	NULL
line	NULL
containing	NULL
herpes-like	NULL
virus	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
3:857-866	NULL
.	NULL

Purtillo	NULL
,	NULL
D.	NULL
T.	NULL
,	NULL
D.	NULL
Deflora	NULL
,	NULL
L.	NULL
M.	NULL
Hutt	NULL
,	NULL
J.	NULL
Bhawan	NULL
,	NULL
J.	NULL
P.	NULL
S.	NULL
Yung	NULL
,	NULL
R.	NULL
Otto	NULL
,	NULL
and	NULL
W.	NULL
Edwards	NULL
.	NULL

1977	NULL
.	NULL

Variable	NULL
phenotypic	NULL
expression	NULL
of	NULL
an	NULL
X-linked	NULL
recessive	NULL
lymphoproliferative	NULL
syndrome	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

297:1077-1081	NULL
.	NULL

Raab-Traub	NULL
,	NULL
N.	NULL
,	NULL
R.	NULL
Pritchett	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1978	NULL
.	NULL

DNA	NULL
of	NULL
3416	NULL
35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

WANG	NULL
ET	NULL
AL	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
.	NULL

III	NULL
.	NULL

Identification	NULL
of	NULL
restriction	NULL
enzyme	NULL
fragments	NULL
which	NULL
contain	NULL
DNA	NULL
sequences	NULL
which	NULL
differ	NULL
among	NULL
strains	NULL
of	NULL
EBV	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

27:388-398	NULL
.	NULL

Rabson	NULL
,	NULL
M.	NULL
,	NULL
L.	NULL
Heston	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
,	NULL
1983	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
rare	NULL
Epstein-Barr	NULL
virus	NULL
variant	NULL
that	NULL
enhances	NULL
early	NULL
antigen	NULL
expression	NULL
in	NULL
Raji	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
80	NULL
:	NULL
2762-2766	NULL
.	NULL

Rickinson	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
,	NULL
L.	NULL
S.	NULL
Young	NULL
,	NULL
and	NULL
M.	NULL
Rowe	NULL
.	NULL

1987	NULL
.	NULL

Influence	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
EBNA	NULL
2	NULL
on	NULL
the	NULL
growth	NULL
phenotype	NULL
of	NULL
virus-transformed	NULL
B	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

61:1310-1317	NULL
.	NULL

Rowe	NULL
,	NULL
M.	NULL
,	NULL
H.	NULL
S.	NULL
Evans	NULL
,	NULL
L.	NULL
S.	NULL
Young	NULL
,	NULL
K.	NULL
Hennessy	NULL
,	NULL
E.	NULL
Kieff	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1987	NULL
.	NULL

Monoclonal	NULL
antibodies	NULL
to	NULL
the	NULL
latent	NULL
membrane	NULL
protein	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
reveal	NULL
heterogeneity	NULL
of	NULL
the	NULL
protein	NULL
and	NULL
inducible	NULL
expression	NULL
in	NULL
virus-transformed	NULL
cells	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

68:1575-1586	NULL
.	NULL

Rowe	NULL
,	NULL
M.	NULL
,	NULL
D.	NULL
T.	NULL
Rowe	NULL
,	NULL
C.	NULL
D.	NULL
Gregory	NULL
,	NULL
L.	NULL
S.	NULL
Young	NULL
,	NULL
P.	NULL
J.	NULL
Farrell	NULL
,	NULL
H.	NULL
Rupani	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1987	NULL
.	NULL

Differences	NULL
in	NULL
B	NULL
cell	NULL
growth	NULL
phenotype	NULL
reflect	NULL
novel	NULL
patterns	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
gene	NULL
expression	NULL
in	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cells	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

6:2743-2751	NULL
.	NULL

Sample	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
Hummel	NULL
,	NULL
D.	NULL
Braun	NULL
,	NULL
M.	NULL
Birkenbach	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1986	NULL
.	NULL

Nucleotide	NULL
sequences	NULL
of	NULL
mRNAs	NULL
encoding	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
proteins	NULL
:	NULL
a	NULL
probable	NULL
transcriptional	NULL
initiation	NULL
site	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83:5096-5100.	NULL
.	NULL

Sample	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1990	NULL
.	NULL

Transcription	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
genome	NULL
during	NULL
latency	NULL
in	NULL
growth-transformed	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:1667-1674	NULL
.	NULL

Sample	NULL
,	NULL
J.	NULL
,	NULL
D.	NULL
Liebowitz	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1989	NULL
.	NULL

Two	NULL
related	NULL
Epstein-Barr	NULL
virus	NULL
membrane	NULL
proteins	NULL
are	NULL
encoded	NULL
by	NULL
separate	NULL
genes	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:933-937	NULL
.	NULL

Shope	NULL
,	NULL
T.	NULL
C.	NULL
,	NULL
D.	NULL
Dechairo	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1973	NULL
.	NULL

Malignant	NULL
lymphoma	NULL
in	NULL
cotton-top	NULL
marmosets	NULL
after	NULL
inoculation	NULL
with	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
70:2487-2491	NULL
.	NULL

Skare	NULL
,	NULL
J.	NULL
,	NULL
J.	NULL
Farley	NULL
,	NULL
J.	NULL
L.	NULL
Strominger	NULL
,	NULL
K.	NULL
O.	NULL
Fresen	NULL
,	NULL
M.	NULL
S.	NULL
Cho	NULL
,	NULL
and	NULL
H.	NULL
zur	NULL
Hausen	NULL
.	NULL

1985	NULL
.	NULL

Transformation	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
requires	NULL
DNA	NULL
sequences	NULL
in	NULL
the	NULL
region	NULL
of	NULL
BamHI	NULL
fragments	NULL
Y	NULL
and	NULL
H.	NULL
J.	NULL
Virol	NULL
.	NULL

55:286-297	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

J.	NULL
Viror	NULL
.	NULL

.	NULL

Wang	NULL
,	NULL
D.	NULL
,	NULL
D.	NULL
Liebowitz	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1985	NULL
.	NULL

An	NULL
EBV	NULL
membrane	NULL
protein	NULL
expressed	NULL
in	NULL
immortalized	NULL
lymphocytes	NULL
transforms	NULL
established	NULL
rodent	NULL
cells	NULL
.	NULL

Cell	NULL
43:831-840	NULL
.	NULL

Wang	NULL
,	NULL
D.	NULL
,	NULL
D.	NULL
Liebowitz	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
truncated	NULL
form	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
infection	NULL
membrane	NULL
protein	NULL
expressed	NULL
in	NULL
virus	NULL
replication	NULL
does	NULL
not	NULL
transform	NULL
rodent	NULL
fibro-blasts	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:2337-2346	NULL
.	NULL

Wang	NULL
,	NULL
D.	NULL
,	NULL
D.	NULL
Liebowitz	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
C.	NULL
Gregory	NULL
,	NULL
A.	NULL
Rickinson	NULL
,	NULL
R.	NULL
Larson	NULL
,	NULL
T.	NULL
Springer	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1988	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latent	NULL
infection	NULL
membrane	NULL
protein	NULL
(	NULL
LMP	NULL
)	NULL
alters	NULL
lymphocyte	NULL
morphology	NULL
,	NULL
adhesion	NULL
,	NULL
and	NULL
growth	NULL
:	NULL
deletion	NULL
of	NULL
the	NULL
amino	NULL
terminus	NULL
abolishes	NULL
activity	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:4173-4184	NULL
.	NULL

Wang	NULL
,	NULL
F.	NULL
,	NULL
C.	NULL
D.	NULL
Gregory	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
,	NULL
D.	NULL
Wang	NULL
,	NULL
M.	NULL
Birkenbach	NULL
,	NULL
H.	NULL
Kikutani	NULL
,	NULL
T.	NULL
Kishimoto	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1987	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
protein	NULL
2	NULL
specifically	NULL
induces	NULL
expression	NULL
of	NULL
the	NULL
B	NULL
cell	NULL
activation	NULL
antigen	NULL
,	NULL
CD23	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:3452-3456	NULL
.	NULL

Wang	NULL
,	NULL
F.	NULL
,	NULL
C.	NULL
Gregory	NULL
,	NULL
C.	NULL
Sample	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
D.	NULL
Liebowitz	NULL
,	NULL
R.	NULL
Murray	NULL
,	NULL
A.	NULL
Rickinson	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1990	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
(	NULL
LMP1	NULL
)	NULL
and	NULL
nuclear	NULL
proteins	NULL
2	NULL
and	NULL
3C	NULL
are	NULL
effectors	NULL
of	NULL
phenotypic	NULL
changes	NULL
in	NULL
B	NULL
lymphocytes	NULL
:	NULL
EBNA-2	NULL
and	NULL
LMP1	NULL
cooperatively	NULL
induce	NULL
CD23	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:2309-2318	NULL
.	NULL

Wang	NULL
,	NULL
F.	NULL
,	NULL
L.	NULL
Petti	NULL
,	NULL
D.	NULL
Braun	NULL
,	NULL
S.	NULL
Seung	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
bicistronic	NULL
Epstein-Barr	NULL
virus	NULL
mRNA	NULL
encodes	NULL
two	NULL
nuclear	NULL
proteins	NULL
in	NULL
latently	NULL
infected	NULL
growth-transformed	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

61:945-954	NULL
.	NULL

Whyte	NULL
,	NULL
P.	NULL
,	NULL
K.	NULL
J.	NULL
Buchkovich	NULL
,	NULL
J.	NULL
M.	NULL
Horowitz	NULL
,	NULL
S.	NULL
H.	NULL
Friend	NULL
,	NULL
M.	NULL
Raybuck	NULL
,	NULL
R.	NULL
A.	NULL
Weinberg	NULL
,	NULL
and	NULL
E.	NULL
Harlow	NULL
.	NULL

1988	NULL
.	NULL

Association	NULL
between	NULL
an	NULL
oncogene	NULL
and	NULL
an	NULL
anti	NULL
oncogene	NULL
;	NULL
the	NULL
adenovirus	NULL
ElA	NULL
proteins	NULL
bind	NULL
to	NULL
the	NULL
retinoblastoma	NULL
gene	NULL
product	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
334:124-129	NULL
.	NULL

Young	NULL
,	NULL
L.	NULL
,	NULL
C.	NULL
Alfieri	NULL
,	NULL
K.	NULL
Hennessy	NULL
,	NULL
H.	NULL
Evans	NULL
,	NULL
C.	NULL
O'Hara	NULL
,	NULL
K.	NULL
C.	NULL
Anderson	NULL
,	NULL
J.	NULL
Ritz	NULL
,	NULL
R.	NULL
S.	NULL
Shapiro	NULL
,	NULL
A.	NULL
Rickinson	NULL
,	NULL
E.	NULL
Kieff	NULL
,	NULL
and	NULL
J.	NULL
I.	NULL
Cohen	NULL
.	NULL

1989	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
transformation	NULL
associated	NULL
genes	NULL
are	NULL
expressed	NULL
in	NULL
tissues	NULL
from	NULL
patients	NULL
with	NULL
EBV	NULL
lymphoproliferative	NULL
disease	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

321:1080-1085	NULL
.	NULL

